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ABSTRACT 
 In recent years the rising cost and increased regulation within the U.S. healthcare system 
have caused medical laboratory tests to become more costly and more frequently required.  As a 
result, insurance premiums are rising, and small independent laboratories are threatened with 
closure as their already narrow margins dwindle.  Concurrently, there have been several incidents 
of contaminants and impurities in pharmaceutical drugs causing hundreds of deaths and thousands 
of illnesses.   These challenges substantiate the need for simple and cost-effective screening tests 
for the presence of disease biomarkers, as well as for contaminants and impurities present in 
pharmaceutical drugs.   
 The following disquisition reports three independent studies, each with the development 
of simple screening tools as its objective.  Paper 1 reports the use of fluorescent lipid 
nanoparticles (liposomes) to detect changes in the species and concentrations of 
glycosaminoglycans (GAGs) in solution.  We conclude that the emission intensity from the 
present fluorophores changes in response to increasing concentrations of GAGs, and can 
distinguish between serum from a healthy patient and serum having the same GAG concentrations 
as an Alzheimer’s disease patient (simulated).   
 Paper 2 reports the use of lipid nanoparticles to detect dangerous over-sulfated 
contaminants in pharmaceutical heparin.  We report that liposomes in the presence of heparin or 
over-sulfated contaminants and Mg
2+
 ions form aggregates, and the size and zeta potential of 
these aggregates is dependent on the heparin/contaminant present.  Further, the variation in 
aggregate zeta potential varies significantly upon heparin contamination, and may be used to 
detect 0.5% contaminant by weight.   
iv 
 
 Paper 3 reports a clinical study to validate the presence of ADAM 12 (a disintegrin and 
metalloproteinase) enzyme in urine as a biomarker for breast cancer detection and diagnosis, as 
well as to monitor the effects of tumor removal on the urinary levels of this enzyme.  We find no 
significant differences between recently diagnosed cancer patients (having undergone no 
treatment for cancer) and age-matched controls having no cancer present.  Significant increases in 
urinary ADAM 12 only occur following surgery.  Overall, we conclude that it is unlikely that a 
screen for urinary ADAM 12 will be useful for the diagnosis of breast cancer.   
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INTRODUCTION 
Rising cost of medical care and the need for simple tests   
Recent and ongoing changes to the laws and policies governing health care have 
produced numerous concerns and queries, particularly concerning how much medical care will 
cost.  While it is not the goal of this disquisition to make political or macro-economic statements 
or predictions on this subject, the general consensus is that costs are increasing!  A recent article 
in Forbes magazine predicts that individual health care insurance policy premiums will increase 
64%-146% in California (a market that traditionally has very competitive rates for individuals)
1
.  
Concurrent to these purported increases in insurance premiums is an increased need for 
laboratory tests, as reported in Dark Daily, a web-based periodical providing alerts on laboratory 
and pathology news and trends.  They point out that 27+ preventative medical services listed that 
must be covered under the new law all require laboratory tests as part of the protocol
2
.  However, 
Dark Daily also reported on May 22, 2013, that many independent medical laboratory testing 
facilities may be forced into bankruptcy by recent cuts to the Medicare Part B Clinical 
Laboratory Price Schedule and Federal funding sequester
3
.  Many of these laboratories—often 
the only clinical laboratory serving their area—must operate on a profit margin of only 3-6% per 
annum; add the 2% fee reduction specified in the sequester, and these companies can no longer 
make a profit
3
.   
 To complicate matters further, a recent Laboratory National Status report sponsored by 
the Center for Disease Control and Prevention indicates high rates of laboratory error.  The 
report cites a number of quality challenges, such as lack of standardization of test values, poor 
quality control, and poor test reproducibility as some of the challenges to be addressed
4
.  The 
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development of simple, inexpensive, and easily interpreted clinical laboratory tests would go a 
long way toward providing a solution for many of these issues. 
Increasing concerns about drug quality   
The last decade has seen a significant number of pharmaceutical drugs contaminated 
before reaching the patient, and has witnessed considerable resulting illness.  In 2007-08, lots of 
heparin were contaminated with over-sulfated chondroitin sulfate, leading to illness and death in 
10 countries globally
5
 (this contamination will be discussed further in the section entitled 
“PAPER 2: An inexpensive, rapid, accurate screen for the presence of dangerous over-sulfated 
heparin contaminants”).  In 2012, steroidal injections contaminated with fungal meningitis 
caused a total of 745 reported meningitis cases, and 58 deaths
*
, according to the Center for 
Disease Control and Prevention
6
.  Also in 2012, cardiac drugs administered to patients in Lahore, 
Pakistan, were contaminated with pyrimethamine, an antimalarial drug.  This contamination 
resulted in 107 confirmed deaths, with over 450 others becoming ill
7
.  Whether such 
contaminations occur by accident or deliberately, there is clearly a need for simple, accurate tests 
to confirm drug quality at all stages of the pharmaceutical supply chain.   
Research significance   
The chapters presented in this disquisition represent three independent studies with three 
corresponding papers either published previously, or currently submitted for publication.  
Throughout the studies presented, the common thread is that of simple and clinically relevant 
detection methods for significant biological compounds; we explore various biochemical 
methods for detection of disease biomarkers, as well as over-sulfated contaminants in heparin.  
                                                 
*
 These numbers reflect death from all causes.  All were confirmed cases of meningitis caused by contaminated 
drug. 
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The compounds or proteins we wish to detect during the presented studies are either potentially 
indicative of a patient’s disease state (i.e. a disease biomarker, as in the chapters entitled PAPER 
1 and PAPER 3), or potentially dangerous over-sulfated heparin contaminants (as in the chapter 
entitled PAPER 2).  For each of these target compounds, a simple detection method could prove 
both medically and economically beneficial.  In order to best consider the potential benefits of 
the presented studies, we will now discuss the goals of these as individual chapters. 
Paper 1: A new method for detection and diagnosis of Alzheimer’s disease  
In this chapter, we develop a method to discriminate between different 
glycosaminoglycans in solution using lipid nanoparticles (liposomes) labeled with a fluorescent 
reporter molecule.  Glycosaminoglycans (GAGs) are carbohydrate polymers composed of 
repeating uronic acid-amino sugar disaccharides
8
 and have numerous physiological functions in 
their various forms, which include chondroitin sulfate
9
, heparin sulfate
10,11
, heparan sulfate
10,12
, 
and hyaluronic acid
13.  There are a number of disease conditions in which the patient’s serum or 
urine GAG concentrations begin to change, such as Schizophrenia
14
, some metastatic 
cancers
15,16, and Alzheimer’s disease17.  Of particular interest is the potential to monitor these 
changes in patients’ to detect and accurately diagnose Alzheimer’s disease.   
 Currently Alzheimer’s disease affects 5.3 million people in the United States alone, 
making it the most common neurodegenerative disease associated with advanced age
18
.  Current 
methods for diagnosis of Alzheimer’s include cognitive and behavioral evaluations, as well as 
brain scans
19
, but the predictive factors for individuals’ risk of developing the disease remain 
largely unknown
20
.  We show in our study presented in PAPER 1 that changes in emission 
intensity from fluorescently labeled liposomes in the presence of different GAGs can 
discriminate between these GAGs in a concentration dependent fashion.  As such, the presence 
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of elevated GAGs in the serum of Alzheimer’s patients could also be detected by these 
liposomes.  We demonstrate that liposomes labeled with pyranine fluorophore show marked 
differences in their fluorescence emission intensities in the presence of dilute serum from a 
healthy individual as compared with dilute simulated serum from an individual with Alzheimer’s 
disease
21
.  As such, we believe that with further development this method may be able to aid in 
the accurate diagnosis of Alzheimer’s disease, as well as monitoring patient risk and prognosis.   
Paper 2: A simple screen for the presence of heparin contaminants  
In this chapter we develop a new screening tool for the presence of dangerous heparin 
contaminants, particularly over-sulfated chondroitin sulfate, using liposomes composed of 99 
mol% 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) and 1 mol% of a lissamine-
rhodamine labeled lipid.  In 2007-08, lots of heparin exported from China were contaminated 
with over-sulfated chondroitin sulfate (OSCS)
22,23
.  Use of this heparin was associated with 
numerous illnesses and deaths in the United States alone
5
, with a total of ten countries worldwide 
affected by the contamination.  The United States Food and Drug Administration now mandates 
that heparin be screened for the presence of this compound.   
 Current screening methods for OSCS—such as 1H NMR and strong anion exchange 
HPLC—are effective, but not without drawbacks: they are expensive, time consuming, and 
require considerable training for their proper interpretation.  A rapid, easily interpreted method 
of screening heparin would thus have considerable economic advantages.   
The method we have developed uses the particular tendency of phosphocholine 
liposomes to aggregate in the presence of sulfated glycosaminoglycans (such as heparin) and 
divalent cations such as Mg
2+
.
 24,25
  The aggregates formed by these liposomes in the presence of 
heparin only have a consistent average aggregate diameter and zeta potential, as measured by 
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dynamic light scattering.  As the heparin becomes contaminated with small quantities of OSCS, 
the size and zeta potential of these aggregates begin to change, reflecting the greater degree of 
sulfation and thus the greater negative charge of this contaminant
26
.  These changes may be 
detected by statistical analysis.  This method presents considerable potential as a screening 
method for pharmaceutical heparin, and with minimal further optimization could be produced as 
a mass-produced product for this purpose.    
Paper 3: ADAM 12 as a potential urinary biomarker for breast cancer   
In this chapter we examine the efficacy of urinary ADAM 12 (A Disintegrin and 
Metalloproteinase enzyme-12) as a viable biomarker for the diagnosis of breast cancer.  As the 
leading cause of cancer deaths in the United States in women from the ages of 40 to 59.5 years, 
breast cancer kills one woman every 13 minutes in the US alone
27
.  However, if breast cancer is 
detected and treated before it becomes metastatic (spreads beyond the breast), the 5-year survival 
rate may be as high as 93%
†
, and as such early detection of breast cancer is critical to patient 
prognosis.  Currently, breast cancer is detected primarily through mammograms and self-exams, 
as well as blood-based biomarkers (e.g. cancer antigen 15-3 and 27.29, carcinoembryonic 
antigen, and HER2/neu)
28,29
.  Unfortunately these biomarkers show little promise regarding early 
detection
30
, and the rising costs of healthcare are making mammograms less available
31
.  The use 
of a urinary biomarker for breast cancer diagnosis could therefore provide a significant 
advantage, both for reduction of medical costs and patient convenience. 
 A disintegrin and metalloproteinase (ADAMs) enzymes are a family of 35 multi-domain, 
zinc-dependent metalloproteinase enzymes.  These enzymes have a variety of physiological roles 
                                                 
†
 This number reflects death from all causes. 
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in healthy tissues
32
; however dysregulation of their transcription or translation has been 
associated with a number of disease conditions, including breast cancer
32
.   
 A study published in 2004 by Roopali Roy, et al., concludes that there is a strong 
correlation between the amount of urinary ADAM 12 in a patient’s urine and their breast cancer 
status and stage
33
.  The authors claim that the elevation in urinary ADAM 12 was significant for 
patients with ductal carcinoma in situ (DCIS), invasive breast cancer (IBC), and metastatic 
cancer. They further state that all patients diagnosed with cancer tested positive for the presence 
of urinary ADAM 12 at a significantly greater rate compared with controls—15% positive for 
controls, 78% positive for atypical ductal hyperplasia/lobular carcinoma in situ, 82% for ductal 
carcinoma in situ, 86% for invasive breast cancer, and 85% for metastatic breast cancer.  These 
results strongly suggest that a screen for the presence of urinary ADAM 12 could be valuable in 
the diagnosis of breast cancer.   
Patients diagnosed with breast cancer and their age matched controls were recruited as 
participants for this study from the Sanford Medical Center and Rodger Maris Cancer Center in 
Fargo, North Dakota in collaboration with Sanford Health (all procedures for this study were 
reviewed and approved by the Sanford Health Institutional Review Board).  Urine was collected 
from the breast cancer patients both prior to any treatment, as well as 2-4 weeks following 
surgery, and subjected to commercially available ELISA (Enzyme Linked Immuno Sorbent 
Assay) tests to quantify the amount of urinary ADAM 12 present.  These quantities were 
compared with age-matched controls.  Interestingly, we find no significant differences between 
the urinary ADAM 12 levels of cancer patients prior to treatment and age-matched controls.  
ADAM 12 levels do become significantly elevated following surgery, and this elevation is more 
significant for patients having undergone more severe surgeries (patients having undergone a 
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mastectomy have more significant elevations than those who underwent a lumpectomy).  Based 
on these data, we must conclude that urinary ADAM 12 is unlikely to be a viable biomarker for 
breast cancer diagnosis.   
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PAPER 1. FLUORESCENT LIPOSOMES FOR DIFFERENTIAL INTERACTIONS WITH 
GLYCOSAMINOGLYCANS 
Abstract  
We have successfully synthesized a lipid containing the pyranine dye as the hydrophilic 
head group.  This lipid was incorporated into liposomes with 1-palmitoyl-sn-glycero-3-
phosphocholine as the major component.  The resultant liposomes displayed differential 
enhancements in fluorescence emission intensity in the presence of nanomolar concentrations of 
different glycosaminoglycans.  Linear discriminant analysis of the fluorescence response data 
demonstrate that the liposomes are able to distinguish between different GAGs.  In addition, we 
also demonstrate that the liposomes incorporating the pyranine lipid are able to distinguish 
between dilute serum from healthy individuals and serum containing elevated chondroitin sulfate 
(simulated serum from an Alzheimer’s disease patient).   
Introduction 
Glycosaminoglycans (mucopolysaccharides) are linear polysaccharides composed of 
repeating disaccharide units of uronic acid and an amino sugar (Figure 1.1).
1
 They may be either 
sulfated or non-sulfated, and are involved in many physiological functions.
2
 In several diseases, 
the serum or urine levels of glycosaminoglycans (GAGs) change relative to that of healthy 
individuals.  For example, abnormal metabolism of the GAGs and glycoproteins present in the 
blood-brain barrier and neuron receptors contribute to abnormally high levels of GAGs in the 
serum of schizophrenics,
3,4
 with a concurrent decrease in urine glycosaminoglycan level.
4,5
 The 
serum concentrations of glycosaminoglycans (uronic acids and chondroitin sulfate) increase 
considerably in Alzheimer’s disease patients relative to that of healthy individuals.6  The urine 
11 
 
GAG concentrations are also elevated for patients with various types of metastatic cancers,
7-9
 and 
for children with acute urinary tract infections.
10
 
 
Figure 1.1. Structures of the glycosaminoglycans (GAGs).  
Usually, the detection of GAGs involves chemical or enzymatic hydrolysis of the 
polymers to smaller units and subsequent conjugation with suitable dyes for spectrophotometric 
or spectrofluorometric detection of the hydrolysis products (often by HPLC).
11,12
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commercially available GAG detection kits based on these principles.
‡
  However, these 
techniques provide the total concentration of the glycosaminoglycans in the sample, and do not 
provide the identity of the GAG present. Nuclear magnetic resonance (NMR), capillary 
electrophoresis (CE) and mass spectrometry (MS) have been used to detect the hydrolysis 
products and to identify the GAGs present in the original samples.
11
 These techniques are 
involved, require specialized equipment and purified, known samples of the hydrolysis products 
for calibration. ELISA-like assays and immunoblotting have been developed for selective 
detection of GAGs.
13,14
  Although these methods are successful in detecting the individual 
GAGs, sensitive biological antibodies are used as the recognition elements. 
Herein, we report the synthesis of a lipid containing the pyranine dye as the hydrophilic 
head group and demonstrate that liposomes incorporating this lipid show differential 
modulations of the emission intensity in the presence of different glycosaminoglycans.  Linear 
discriminant analysis of the fluorescence response data demonstrate that the liposomes are able 
to distinguish between different GAGs.  In addition, we also demonstrate that these liposomes 
(containing the pyranine lipid) are able to distinguish between dilute serum from healthy 
individuals and serum containing elevated chondroitin sulfate (simulated serum from an 
Alzheimer’s disease patient).  With further development, we anticipate that this fluorescence-
based approach to detect the individual GAGs (without prior chemical or enzymatic hydrolysis 
or without using biological antibodies) will be invaluable for accurate and early diagnosis of 
these diseases.   
 
                                                 
‡
 GAG detection kits are available from several suppliers. For example:  Biocolor Ltd (UK);  Kamiya Biomedical 
Company, Seattle, WA (US); ALPCO Diagnostics, Salem, NH (US) etc. 
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Materials and methods 
Materials: All reagents were purchased from either TCI America or Alfa-Aesar and were 
used as received.  Table 1.1 shows the glycosaminoglycans used, and their respective molecular 
weights.   
Table 1.1. Glycosaminoglycans used and 
respective molecular weights 
GAG Used MW (kDa) 
Chondroitin Sulfate 35 
Dermatan Sulfate 30 
Dextran Sulfate 40 
Heparin Sulfate 13.5 
Hyaluronic Acid 1400 
 
The dansyl, rhodamine and POPC lipids were purchased from Avanti Polar Lipids.  
Human serum was purchased from Sigma-Aldrich.  Probe sonication was carried out using a 
Misonix Microson Ultrasonic Cell Disruptor, with a VWR digital heatblock for temperature 
control.  Fluorescence spectra were recorded using a Horiba Jobin Yvonne FluoroMax-4 
spectrofluorometer.   
Synthesis of the pyranine lipid: The synthetic details are provided in Appendix A. 
Preparation of liposomes: For pyranine-containing liposomes, 1.2 mL of POPC solution 
in chloroform (2 mg/mL), and 4.2 mL of pyranine lipid solution in chloroform (0.01 mg/mL) 
were added to a 10 mL round-bottom flask. For lissamine-rhodamine-containing liposomes 1.2 
mL of POPC solution in chloroform (2 mg/mL), and 4 mL of lissamine-rhodamine lipid solution 
in chloroform (0.01 mg/mL) were added to a 10 mL round-bottom flask. For dansyl-containing 
liposomes, 1 mL of POPC solution in chloroform (2 mg/mL), and 1.74 mL of dansyl lipid 
solution in chloroform (1 mg/mL) were added to a round-bottom flask.  The solutions were 
evaporated using a rotary evaporator at 50 
o
C for 10 minutes. The resulting lipid thin film was 
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stored in a desiccator for 8 hours or overnight.  The lipid thin film was hydrated with 2 mL of 25 
mM HEPES buffer (pH 8) for 1 hour at 50 ºC with rotation and then probe-sonicated at 70 ºC for 
45 min.  The liposomes were stored at room temperature (22 ºC) in darkness for 1 hour and then 
extruded 15 times through a 100 nm filter at 70 ºC.  The extruded liposomes were allowed to 
come to room temperature (15 min) before use.   
Calculation of fluorophore on outer leaflet:  
Equation used is as follows: 
                                                                               
                                                                             
 
Therefore, for 1.8 mL final volume of pyranine-containing liposomes, the calculation is as such: 
(0.6) x (0.000044g) x (1000)/(1329.61g) x (1.8mL) = 1.1 x 10
-5
 M, or 11µM stock solution of 
liposomes. This solution was then diluted for use in the same buffer used for hydration of the 
thin film (see above).  In addition, it is this concentration (that of the fluorophore on the outer 
liposome leaflet) that was used to express the concentrations of liposomes used during 
fluorescence emission studies.   
Fluorescence spectroscopic studies: To determine the changes in fluorescence emission 
upon addition of GAGs to each fluorophore-containing liposome, the following sequential 
additions were made to a quartz fluorimeter cell.  Each sample was measured six times for the 
statistical analysis of the data. 
1. 193 L of 25 mM HEPES buffer, pH 8. 
2. 5 L liposomes solution (200 nM solution for pyranine and rhodamine liposomes, and 8 
M for dansyl liposomes (final concentration of 5 nM for pyranine and rhodamine, 200 
nM for dansyl liposomes). Following this addition, the solution was excited six times at a 
15 
 
wavelength corresponding to the excitation wavelength of the fluorophore present, and 
each excitation was followed by collection of the emission spectrum. 
3. 2 L GAG solution in 25 mM HEPES (100 nM solution added—final concentration 1 
nM).  
4. 1.8 L GAG solution (1 µM solution added—final concentration 10 nM).  
5. 8 L GAG solution (1 µM solution added—final concentration 50 nM). 
6. 10 uL GAG solution (1 µM solution added—final concentration 100 nM). 
The maximum emission wavelength for each fluorophore was recorded; data at this wavelength 
for all cycles was collected and used for data analysis. 
Experiments with human serum: Normal human serum was diluted 10,000 times using 
25 mM HEPES buffer at pH 8.  Chondroitin sulfate was added to bring the concentration up to 
48 nM from 26 nM.  This corresponds to 8.1 mg/dL of uronic acid in the serum without dilution 
(similar to that observed for Alzheimer’s disease patients).  The serum was diluted so that the 
concentration of chondroitin sulfate is close to 50 nM (the concentration where the pyranine 
liposomes has the best discriminating ability). An aliquot (1 mL) of each serum mixture was 
withdrawn and 5 L solution of the pyranine liposomes (1 M pyranine concentration in the 
outer leaflet of the liposomes) was added to each, resulting in final concentration of 5 nM 
pyranine in the outer lipid layer liposomes.  A portion of the liposome-serum mixture (200 L) 
was used in the fluorescence experiments. 
Results and discussion 
GAGs are known to interact with liposomes and depending on the concentration of the 
GAG, this leads to liposomal aggregation.
15,16
  We reasoned that this interaction can be 
modulated and monitored by incorporating lipids with charged fluorophores (as head groups) in 
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the liposomes.  With this goal, we synthesized a lipid with the pyranine dye as the hydrophilic 
head group (Figure 1.2). For comparison, we selected two other commercially-available lipids 
incorporating the lissamine rhodamine and dansyl moieties as the hydrophilic head groups 
(Figure 1.2). 
The synthesis of the pyranine lipid started with the commercially available pyranine dye 
(Figure 1.2).  The phenolic hydroxyl group was alkylated to produce the compound 4 containing 
the carboxylic acid moiety.  The compound 4 was subsequently conjugated with the synthesized 
bis-oleoyl lipid 1 to produce the desired pyranine lipid as a yellow waxy solid.  We used the 
racemic 2,3-diaminopropanoic acid in the synthesis, resulting in the racemic form of the 
pyranine lipid.   
We prepared liposomes with 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) 
as the major lipid and monitored changes in fluorescence intensity in the presence of varying 
concentrations of five different GAGs (heparin sulfate, dermatan sulfate, chondroitin sulfate, 
dextran sulfate, and hyaluronic acid, Figure 1.1).  We hypothesized that the presence of different 
GAGs will cause varying degrees of liposomal aggregation, causing each fluorophore to exhibit 
different patterns of fluorescence emission intensity changes. This will therefore serve to not 
only detect GAGs in solution, but also to distinguish between different glycosaminoglycan types. 
The liposomes were prepared in 25 mM HEPES buffer (pH = 8.0) by the thin film 
hydration method.
17
  Unilamellar vesicles were generated by probe sonication followed by 
repeated extrusions through membranes of 100 nm pore sizes at 70 
o
C (Appendix A).
17
 The 
average diameter of the extruded liposomes was observed to be 88 + 5 nm (by dynamic light 
scattering). We used 1 mol% of the pyranine lipid or the rhodamine lipid in the liposomes.  A 
significantly higher amount of the dansyl lipid (40 mol%) was required in the liposomes to 
17 
 
compensate for its lower quantum yield.
18
  Differential scanning calorimetric studies revealed 
that the fluorophore lipids were mixed in the lipid bilayer of the liposomes (data not shown). 
 
  
Figure 1.2. Fluorescent lipid structures. Structures of the lipids with pyranine, lissamine 
rhodamine and dansyl as the head groups and the synthesis of the pyranine lipid. 
 
To conduct fluorescence spectroscopic studies, liposomes from each batch were 
incubated with four different concentrations (1 nM, 10 nM, 50 nM, and 100 nM) of each of the 
glycosaminoglycans. The low concentrations of the GAGs in 25 mM HEPES buffer (pH = 8.0) 
ensure that the molecules are completely ionized and the degree of ionization is not influencing 
the fluorescence spectra from the liposome-incorporated dyes. Six fluorescence emission spectra 
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were recorded for each concentration of each glycosaminoglycan, and these were compared with 
the corresponding emission spectra from the liposomes in the absence of GAGs.  The ratios of 
emission intensities from liposomes alone to that in the presence of GAGs (Emlip/EmGAG) were 
calculated for each spectrum at the peak emission wavelength, and these ratio data were 
subjected to linear discriminant analysis.
19-21
   
We observed that liposomes containing the selected fluorophores respond differently to 
the presence of the different GAGs tested.   Figure 1.3B depicts the ratios of the fluorescence 
emission intensity of the pyranine liposomes for each GAG at 50 nM concentration (ex = 390 
nm).  Figure 1.3A depicts representative full fluorescence emission spectra for these liposomes 
in the presence of each GAG.   
 
Figure 1.3. Liposome fluorescence spectra. The fluorescence spectra  (A) of the liposomes 
incorporating the pyranine lipid (λex = 390 nm) in the presence of 50 nM of each of the 
glycosaminoglycans are shown. The emission intensity ratios in the absence and presence of 
added GAGs are shown in (B). The GAGs include chondroitin sulfate (olive), dextran sulfate 
(blue), heparin sulfate (red), hyaluronic acid (magenta), and dermatan sulfate (brown). The black 
trace in (A) is for the liposomes in the absence of any added GAGs. The data points in (B) are 
connected by straight lines. 
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Notable from this figure is that each GAG produces a different Emlip/EmGAG ratio (Figure 1.3B; 
the plots for the liposomes incorporating the other fluorophores are included in Appendix A).  
Transmission electron microscopy of the liposomes after the addition of 50 nM GAGs indicated 
aggregation leading to increase in size (Figure 1.4); however, we did not observe any precipitate 
formation. 
 
Figure 1.4.  TEM micrographs of pyranine liposomes in buffer only and with chondroitin 
sulfate. Transmission electron micrographs of the pyranine liposomes in buffer (2) and in the 
presence of 50 nM chondroitin sulfate (2) are shown.  The magnification was 79,200 (1 cm in the 
figures corresponds to 250 nm in size).  
 
To determine whether a change in the molecular weight of the glycosaminoglycan would 
alter the fluorescence intensity change, we repeated the studies with another sample of 
chondroitin sulfate with a lower molecular weight (20 kDa) and compared the responses with 
those from the chondroitin sulfate of molecular weight 35 kDa.   We observed that the higher 
molecular weight chondroitin sulfate caused more pronounced decreases in the emission 
intensity from the pyranine and dansyl-containing liposomes (Appendix A). It is likely that the 
higher molecular weight GAG leads to a greater degree of liposomal aggregation, and a greater 
decrease in emission intensity from the liposomes. However, the reverse was observed with 
lissamine-rhodamine-containing liposomes, with the lower molecular weight chondroitin sulfate 
causing a greater change in emission intensity (Appendix A).  Reasons for this observation are 
A B 
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unclear, and further investigation is needed to fully deduce the mechanism responsible for this 
change.   
Linear discriminant analysis (LDA) is used to identify the predictive power of the 
liposomes (see Appendix A for details).
19-21
 Emission intensity data from the liposomes (the 
predictor variables) and the five GAGs shown in Table 1.1 (the dependent variables) were 
replicated a total of six times, yielding a sample of 30 observations with four variables (one for 
each liposome and one identifying the GAG).  All statistical analyses were conducted using the 
PASW (formerly SPSS) Statistical Package, Version 18.  
 Table 1.2 shows means, F-statistics and Wilks’ Lambda values for each liposome, 
disaggregated by GAGs.  We note that smaller values for the Wilks’ Lambda indicate a greater 
potential for the liposomes to discriminate across GAGs.
22
 All F-statistics have associated p-
values less than 0.05, indicating significant differences exist across group means for each GAG.  
For the chondroitin sulfate, dextran sulfate, heparin sulfate and hyaluronic acid, the dansyl 
liposomes have the highest mean fluorescence values.  The pyranine liposomes have the second 
highest mean values, followed by rhodamine liposomes.   
Table 1.2. Tests of equality of group means 
GAG Pyranine
[a,b]
 Rhodamine
[a,b]
 Dansyl
[a,b]
 
Chondroitin Sulfate 1.562 1.297 1.563 
Dermatan Sulfate 1.942 1.447 1.412 
Dextran Sulfate 1.334 1.247 1.541 
Heparin Sulfate 1.729 1.517 1.862 
Hyaluronic Acid 1.487 1.124 2.243 
Wilks’ Lambda 0.068 0.214 0.560 
F-Statistic  85.829 22.898 4.904 
P-Value  <0.001 <0.001 1.541 
[a] first panel provides group-specific means [b] second panel provides statistics and p-values. 
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The remaining GAG (dermatan sulfate) has the highest mean emission ratios when 
combined with pyranine, followed by dansyl and rhodamine containing liposomes.  Wilks’ 
Lambda values are lowest for pyranine, followed by rhodamine and dansyl liposomes.     Chi-
square tests indicate that three canonical functions are sufficient to explain our 5 GAGs (see 
Appendix A).  Of these, the first canonical function is most important, as it explains 96.3% of the 
variation across GAGs.  The remaining functions explain 3.0% and 0.7%, respectively.  As such, 
we focus primarily on the first discriminant function.  Figure 1.5 shows a canonical function plot 
of the first two canonical functions (explaining 99.3% of the variation in the GAGs).  Note that 
each of the GAGs is clearly distinguished as a group in the plot.  Moreover, traditional and cross-
validated discriminant functions corrected predict 100% and 93.3% of the GAGs, respectively, 
indicating a high likelihood of interval validity.           
To assess the overall contribution of each liposome to the discriminatory power of the 
LDA, we constructed cumulative potency indices (Appendix A). The potency indices suggest 
that pyranine (potency value = 0.215) provides the largest overall contribution to the model’s 
ability to distinguish emission intensities across GAGs (rhodamine potency index = 0.057; 
dansyl potency index = 0.012).  
The LDA results have a clear and intuitive interpretation; namely, that the pyranine 
liposomes are the “best” determinant of GAGs.  Dansyl liposomes are identified as the least 
“potent” discriminator, even though its emission intensities are relatively high (Table 1.2).  The 
Wilks’ Lambda and structure matrices (see Appendix A for the latter) suggest that this is at least 
partly attributable to excess variation in dansyl emission intensities, which offsets the high mean 
values.  
22 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5. Canonical correlation plot. Canonical correlation plot between two largest 
canonical correlations and each of the five GAGs: chondroitin sulfate (group 1), dermatan sulfate 
(group 2), dextran sulfate (group 3), heparin sulfate (group 4) and hyaluronic acid (group 5).  
 
   One possible limitation of the analysis is that we have chosen a specific (50 nM) 
concentration to conduct our experiments.  To check the robustness of our results, we replicated 
the LDA for the 100 nM concentrations (Appendix A). The results are qualitatively (but not 
quantitatively) similar to those at 50 nM.  
 Subsequently, we proceeded to determine if the pyranine-containing liposomes are 
capable of distinguishing an increase in GAG concentration in a complex mixture of proteins and 
other biomolecules, e.g., dilute human serum. According to the National Institute on Aging, 
currently there is no biochemical test to detect Alzheimer’s disease.  Indirect methods are used 
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by physicians for diagnosis.
§
  However, it has been reported that the serum concentrations of 
glycosaminoglycans (uronic acids) increase in Alzheimer’s disease patients (about 8.4 + 0.8 
mg/dL) relative to that of healthy individuals (about 4.6 + 0.5 mg/dL).
6
  Chondroitin sulfate 
concentration in the serum increases from about 0.58 mg/dL (healthy individuals) to about 2.36 
mg/dL for Alzheimer’s disease patients.6 The LDA analysis indicated that the pyranine-
containing liposomes are capable of distinguishing different GAGs at 100 nM and 50 nM 
concentrations.  It follows that the pyranine liposomes have the capability to distinguish the 
GAGs in a very dilute human serum from an Alzheimer’s disease patient (diluted 104 times).   
  In order to simulate serum from Alzheimer’s disease patients, we spiked commercially 
available human serum (Sigma Chemical Company) with added chondroitin sulfate (MW: 35 
kDa) such that the uronic acid concentration is about 8 mg/dL.  We noted, a priori, that it is an 
increase in not one, but rather several GAGs which contributes to the overall increase in GAG 
concentration in Alzheimer’s disease patients.6 The use of chondroitin sulfate only as the GAG 
of choice is to provide a relevant model system to determine if the pyranine liposomes are 
capable of distinguishing changes in GAG concentration in a complex mixture of other 
physiological molecules.  We noted also that the increase in chondroitin sulfate in Alzheimer’s 
disease patients from that of healthy patients is among the highest percentage increases of all the 
GAGs, while also making up one of the highest fractions of the total GAGs present.
6
 We diluted 
the simulated disease serum appropriately so that the concentration of the chondroitin sulfate is 
about 48 nM.  
                                                 
§
 Reported by the National Institutes of Health, National Institute on Aging; http://www.nia.nih.gov; updated 
January 10, 2011; accessed on April 18, 2011. 
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Figure 1.6.  Pyranine fluorescence in normal serum vs. Alzheimer’s serum.  The 
fluorescence emission spectra for the pyranine liposomes (ex = 390 nm) in the presence of 
diluted healthy serum (blue) and simulated Alzheimer’s disease serum (red) are shown.   
 
Results from the human serum experiment are shown in Figure 1.6.  We observed a 
considerable decrease in the emission intensity from the pyranine liposomes in the presence of 
simulated Alzheimer’s disease serum (Figure 1.6, red trace). It should be noted that the 
commercially available kit can detect the total concentrations of the GAGs (after enzymatic  
hydrolysis) with micromolar detection limits.
13
 In contrast, the emission intensity from the 
pyranine liposomes changes considerably in the presence of 48 nM chondroitin sulfate (without 
prior enzymatic hydrolysis of the polymer). These results suggest that the pyranine fluorophore-
containing liposomes may be very valuable in the successful diagnosis of Alzheimer’s disease by 
monitoring the levels of the GAGs in the serum.  The utility of such a test could be magnified 
further if the patient could be tested early in life, and then subsequently over time, monitoring 
any changes. 
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Conclusions 
We have successfully synthesized a lipid with the pyranine dye as the hydrophilic head 
group. We have demonstrated (by fluorescence spectroscopy) that liposomes (with POPC as the 
major lipid component) incorporating suitable dyes will differentially interact with the different 
glycosaminoglycans. Linear discriminant analysis indicated that the liposomes incorporating the 
synthesized pyranine lipid have the highest discriminating ability amongst the GAGs.  These 
liposomes are capable of distinguishing different levels of GAGs (e.g., chondroitin sulfate) even 
in a complex mixture of physiological molecules (human serum). 
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PAPER 2. GLYCOSAMINOGLYCAN-MEDIATED SELECTIVE CHANGES IN THE 
AGGREGATION STATES, ZETA POTENTIALS, AND INTRINSIC STABILITY OF 
LIPOSOMES 
Abstract 
Though the aggregation of glycosaminoglycans (GAGs) in the presence of liposomes and 
divalent cations has been previously reported, the effect of different GAG species, as well as 
minor changes in GAG composition on the aggregates formed is yet unknown.  If minor changes 
in GAG composition produce observable changes in liposome aggregate diameter or zeta 
potential, such a phenomenon may be used to detect potentially dangerous over-sulfated 
contaminants in heparin.  We studied the mechanism of the interactions between heparin and its 
over-sulfated glycosaminoglycan contaminants with liposomes. Herein, we demonstrate that 
Mg
2+
 acts to shield the incoming glycosaminoglycans from the negatively-charged phosphate 
groups of the phospholipids, and that changes in the aggregate diameter and zeta potential are a 
function of glycosaminoglycan species and concentration, as well as liposome bilayer 
composition.  These observations are supported by TEM studies.  We have shown that 
organizational states of the liposome bilayers are influenced by the presence of GAG and excess 
Mg
2+
, resulting in a stabilizing effect which increases the Tm value of DSPC liposomes; the 
magnitude of this effect is also dependent on GAG species and concentration present.  There is 
an inverse relationship between the percent change of aggregate diameter and percent change of 
aggregate zeta potential, as a function of GAG concentration in solution.  Finally, we 
demonstrate that the diameter and zeta potential changes of POPC liposome aggregates in the 
presence of different over-sulfated heparin contaminants at low concentrations allow accurate 
detection of over-sulfated chondroitin sulfate at concentrations as low as 1 mol%. 
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Introduction 
Glycosaminoglycans (GAGs) are linear polysaccharides composed of disaccharide units 
of an amino sugar and uronic acid
1
.  When incubated with phosphatidylcholine liposomes and 
divalent cations, GAGs cause the aggregation of liposomes
2,3
.  The interaction between liposome 
charge and GAG concentration to cause this effect has been well documented
2-5
.  However, 
studies conducted to date have focused primarily on mechanism of GAG binding, and have 
limited investigation of how average aggregate diameter and zeta potential are influenced by the 
species of GAG present in solution.  In addition, there is no mention of how average aggregate 
diameter and zeta potential may co-vary as a function of GAG species and/or concentration, nor 
is information on how small changes in GAG composition affect these factors presently 
available.  In the current study, we address a number of questions: do liposome aggregates 
demonstrate differences in their average aggregate diameter and zeta potential as a function of 
the GAG present in solution?  If such changes are observed, how do the original diameter of the 
liposomes and the concentration of the GAG present influence these changes in aggregate 
diameter and zeta potential?  Finally, if the composition of GAG present in solution varies 
slightly, can these changes in zeta potential and diameter be used to detect such variations in 
GAG composition?  If so, such a phenomenon may prove useful in various industries, 
particularly the drug industry to detect potentially dangerous over-sulfated contaminants in 
heparin.   
Heparin is a naturally occurring GAG which, when fully sulfated, has three sulfate 
groups per repeating disaccharide unit, making it the most negatively charged naturally occurring 
polyelectrolyte in mammalian tissues
6
.  Its primary physiological function is highly varied; 
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however its pharmaceutical form (which is typically purified either from porcine intestine or 
bovine lung) is widely utilized as a drug for the prevention of blood clots in surgery patients
7
.   
In 2007 – 2008, several batches of heparin were found to be contaminated with over-
sulfated chondroitin sulfate (OSCS), a product prepared by the synthetic oversulfation of 
chondroitin sulfate
8
, at levels 0.5% by weight to 28% by weight
9
.   Over-sulfated chondroitin 
sulfate has similar but considerably reduced physiological effects as compared to heparin; the 
anticoagulant effect of oversulfated chondroitin sulfate is approximately 20-25% of that is given 
by heparin
3
. In addition, its intravenous administration was associated with numerous allergic 
reactions, including 149 deaths
10
.  The adverse effects of oversulfated chondroitin sulfate result 
from a potent anaphylactic response caused by the activation of the kinin-kallikrein pathway, 
leading to the release of bradykinin
11
.  Other over-sulfated GAGs have also been shown to 
modulate this response
12
. 
To circumvent the onset of above noted side effects, many techniques have been 
explored/ developed for the detection of over-sulfated GAG contaminants in commercial 
preparations of heparin. These include 
1
H NMR spectroscopy
13
, potentiometric strip tests
14
, 
enzyme immunoassay (ELISA)
15
, polyanionic sensors
16
, colorimetric assays
17
, and activated 
partial thromboplastin times (aPTT) and prothrombin times (PT) performed with sheep and 
human plasma
18
.  While each of these techniques presents advantages, all require specialized 
equipment, highly-trained personnel, and/or considerable time to obtain results.  Approximately 
one billion doses of heparin are produced each year
19
, and therefore a fast, simple, and readily 
available screen for the presence of over-sulfated contaminants would prove beneficial, both 
from the  safety and  economic standpoint.  In pursuit of developing easily adaptable and 
sensitive protocol for detection of oversulfated GAG contaminates in heparin preparations, we 
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investigated the aforementioned tendency of liposomes to aggregate in the presence of GAG and 
Mg
2+
, varying both liposome diameter and composition, as well as GAG species and 
concentration.  Sensitivity of the changes in aggregate diameter and zeta potential with respect to 
these parameters were our interest.  
Materials and methods 
Materials and synthesis of over-sulfated GAGs: Chondroitin-6-sulfate, dermatan 
sulfate, and heparin were sourced from Spectrum Chemical Corp., CalBiochem, and Alfa Aesar, 
respectively.  Each was over-sulfated using the procedures published by Maruyama, et al
3
 and 
Nagasawa, et al
20
. 
Preparation of liposomes for aggregation: Stock solutions of 1-palmitoyl-2-oleoyl-sn-
glycero-3-phosphocholine (POPC, commercially available from Avanti Polar Lipids, Alabaster, 
AL) and 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC, commercially available from 
Avanti Polar Lipids, Alabaster, AL) were prepared in chloroform at a concentration of 2 mg/mL.  
Stock solution of 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B 
sulfonyl) (ammonium salt) (rhodamine lipid, commercially available from Avanti Polar Lipids, 
Alabaster, AL) was prepared in chloroform at a concentration of 0.01 mg/mL.  Stock solution of 
pyranine lipid was prepared in chloroform at a concentration of 0.01 mg/mL.  Lipid mixtures 
containing POPC were obtained by combining 2.4 mL POPC stock solution, and either 8.0 mL 
rhodamine lipid stock solution or 8.4 mL pyranine lipid stock solution.  Mixtures containing 
DSPC were prepared by combining 2 mL DSPC stock solution and 6.5 mL rhodamine lipid stock 
solution.   
The resulting mixtures had molar ratios of 99:1 POPC (or DSPC):rhodamine 
lipid/pyranine lipid, respectively.   The mixture was subjected to rotary evaporation at 50ºC for 
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15 minutes, forming a thin film adhering to the sides of the flask.  This thin film was then dried 
overnight under high vacuum to ensure complete removal of solvent.  Lipid films containing 
POPC as the main lipid were then hydrated with 4.0 mL of 25 mM HEPES buffer at pH 8 by 
rapid rotation in a 50ºC water bath for 1hr.  Lipid films containing DSPC as the main lipid were 
hydrated with 4.0 mL of 25 mM HEPES buffer at pH 8 by rapid rotation in a 70ºC water bath for 
1hr.  The procedure now varies for production of 50 nm, 200 nm, and 500 nm liposomes:   
 For 50 nm diameter liposomes (POPC liposomes only): the hydrated solution was 
probe sonicated at 70ºC for 45 minutes, followed by extrusion at 70 ºC (15 times) 
through polycarbonate membrane filters (100 nm pore size).  The average diameter of 
the prepared liposomes (by DLS) was approximately 55 nm + 25 nm.   
 For 200 nm diameter liposomes (POPC and DSPC liposomes):  the hydrated solution 
was immediately extruded at 70 ºC (15 times) through polycarbonate membrane filters 
(100 nm pore size).  Average measured diameters (by DLS) were approximately 185 + 
8 nm and 250 + 90 nm for POPC and DSPC liposomes, respectively.  
 For 550 nm diameter liposomes (POPC liposomes only):  Following hydration, the 
resulting large vesicles were found to have an average diameter of 550 + 70 nm (by 
DLS).  These liposomes were used as such. 
The final volume of each respective liposome solution was then measured using the extrusion 
syringes, and the total lipid per unit volume calculated from this volume.  All liposome solutions 
were diluted to 1.4 mM total lipid before use.   
Mechanistic studies--influence of GAG species and Mg
2+
 on diameter and zeta 
potential of aggregates:  DSPC or POPC liposomes (200 nm diameter only) were incubated for 
15 minutes at room temperature in the presence and absence of Mg
2+
 (33.4 mM final 
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concentration), as well as the presence and absence of heparin.  Mixtures were produced 
according to Table 2.1 below. 
Table 2.1. Preparation of liposomes for diameter and zeta potential mechanism tests 
(volume in L) 
 
HEPES buffer 
(25 mM, pH8) 
Liposomes (1.4 
mM total lipid) 
MgSO4 (2 M in 
HEPES) 
GAG (1 M 
in HEPES) 
Liposomes only 
306 50 --- 
--- 
Liposomes + GAG 
246 50 --- 
60 
Liposomes + Mg
2+
 
300 50 6 
--- 
Liposomes + Mg
2+
 + GAG 
240 50 6 
60 
 
Each mixture was allowed to incubate at room temperature for 15 minutes before reading.  
One hundred µL of this aggregated solution was mixed with 900 µL HEPES buffer at pH 8 in a 
disposable polystyrene cuvette, and read on a Malvern Zetasizer Nano ZS90 with the following 
settings: 5 measurements, each an average of 10 reads, each read 10 sec; 90° read angle; 60 
second pre-equilibration; Auto Attenuation off, manual attenuation set to 7.   For the 
corresponding zeta potential measurements, liposomes were aggregated in the same way as 
above.  Zeta potential was read on a Malvern Zetasizer Nano ZS90 with the following settings: 5 
measurements, each an average of 10 reads, each read 10 seconds; 60 second pre-equilibration; 
automatic attenuation on; automatic voltage selection on.  
Mechanistic studies--influence of GAG species and concentration on the saturation 
of aggregate diameter and zeta potential:  For tests with individual GAGs, POPC and DSPC 
liposomes were aggregated in the presence of eight different concentrations of each GAG 
(heparin, over-sulfated chondroitin sulfate, over-sulfated dermatan sulfate, or over-sulfated 
heparin) in preparation for DLS, according to Table 2.2 below.   
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Table 2.2. Preparation of liposome aggregates for saturation tests (all volumes in L) 
 
HEPES buffer (25 
mM, pH 8) 
Liposomes (1.4 
mM total 
lipid) 
MgSO4 at 2 
M 
GAG (concentration 
in parentheses) 
Liposomes only + Mg
2+
 
300 50 6 
--- 
100 nM GAG 
264 50 6 
35.6 (1 M) 
500 nM GAG 
122 50 6 
178 (1 M) 
1 M GAG 
296 50 6 
3.6 (100 M) 
10 M GAG 
264 50 6 
35.6 (100 M) 
50 M GAG 122 50 6 178 (100 M) 
100 M GAG 264 50 6 
35.6 (1 mM) 
250 M GAG 211 50 6 
89 (1 mM) 
500 M GAG 122 50 6 
178 (1 mM) 
 
Measurement of aggregate diameter and zeta potential proceeded in the same way as 
stated above.  Three measurements were collected for each GAG concentration for both average 
diameter and zeta potential, each an average of 10 reads, each read 10 seconds.  Equipment 
settings remained the same. 
TEM imaging: To aggregate liposomes, 50 L of liposomes (200 nm diameter) at 1.4 
mM, were incubated with 60 L of GAG at 1 µM (approximately 20% v/v, 170 nM final 
concentration) and 6 µL of MgSO4 at 2 M in 240 µL HEPES buffer at pH 8 for 15 minutes at 
room temperature.  For liposome only control, 60 µL GAG was substituted with 60 µL 
additional HEPES buffer.  Copper TEM grids (300-mesh, formvar-carbon coated, Electron 
Microscopy Sciences, Hatfield, Pennsylvania, USA) were prepared by applying a drop of 0.01% 
poly-L-lysine, allowing it to stand for 30 seconds, wicking off the liquid with torn filter paper, 
and allowing the grids to air dry.  A drop of the aggregated liposome suspension was placed on a 
prepared grid for 30 seconds and wicked off; grids were allowed to air dry again.  
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Phosphotungstic acid 1%, pH adjusted to 7-8, was dropped onto the grid containing the liposome 
sample, allowed to stand for 1.5 min, and wicked off.  After the grids were dry, images were 
obtained using a JEOL JEM-2100 LaB6 transmission electron microscope (JEOL USA, Peabody, 
Massachusetts) running at 200 keV.   
Differential scanning calorimetry: DSPC liposomes were incubated with 1 M and 250 
M GAG for 15 minutes at room temperature, before being degassed for 15 minutes and loaded 
into a Nano DSC (TA instruments New Castle, DE) without further dilution.  A sample of DSPC 
liposomes incubated with only Mg
2+
 was used as the control.  The DSC reference cell was filled 
with HEPES buffer at 25 mM, pH 8, containing 33.4 mM MgSO4, the same as that of the 
samples.  Machine was pressurized to three atmospheres, and scans were conducted from 25 °C 
to 75 °C, and rate of temperature change was 2 °C/minute.  Heat required during transition was 
calculated using NanoAnalyze software provided by the instrument vendor, using the sigmoidal 
baseline function to produce the pre- and post-transition baseline. 
Mechanistic studies—combined influence of liposome diameter and GAG 
concentration on diameter and zeta potential changes:  POPC liposomes of diameters 50, 
200, and 550 nm diameter liposomes were each incubated with heparin, OSH, OSCS, and OSD 
(individually) at concentrations of 50, 170, and 500 nM.  Measurement of aggregate diameter 
and zeta potential were measured in the same way as stated above.  Five measurements were 
collected for each GAG concentration for both diameter and zeta potential, each an average of 10 
reads, each read 10 seconds.  Equipment settings remained the same.  Following collection of 
data, each over-sulfated contaminant was compared to the corresponding measurement of 
heparin by calculating the percent change from heparin, using the following formula:  
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The same formula was applied to calculate zeta potential percent change.   
Heparin contamination studies:  For contaminated heparin studies, final concentrations 
of 170 nM and 500 nM total GAG were used with 200 nm and 500 nm diameter liposomes, 
respectively.  Solutions of heparin with an over-sulfated contaminant were prepared according to 
Tables 2.3 and 2.4 below.   
Table 2.3. Preparation of liposome aggregates for 170 nM contamination study (all 
volumes in L) 
 HEPES 
buffer (25 
mM, pH 8) 
Liposomes 
(1.4 mM total 
lipid) 
MgSO4 
at 2 M 
Heparin (1 
µM 
concentration) 
Over-sulfated 
contaminant 
Heparin only 
240 50 6 60 
-- 
0.5 mol% 
contamination 
237.3 50 6 59.7 
3 (100 nM) 
1.0 mol% 
contamination 
234.3 50 6 59.4 
6 (100 nM) 
2.5 mol% 
contamination 
240 50 6 58.5 
1.5 (1 µM) 
5.0 mol% 
contamination 
240 50 6 57 
3 (1 µM) 
10.0 mol% 
contamination 
240 50 6 54 
6 (1 µM) 
15.0 mol% 
contamination 
240 50 6 51 
9 (1 µM) 
20.0 mol% 
contamination 
240 50 6 48 
12 (1 µM) 
30.0 mol% 
contamination 
240 50 6 42 
15 (1 µM) 
 
Measurement of aggregate diameter and zeta potential proceeded in the same way as 
stated above.  Five measurements were collected for each GAG concentration for both diameter 
and zeta potential, each an average of 10 reads, each read 10 seconds.  Equipment settings 
remained the same. 
Statistical analysis: Analysis of variance and Dunnett’s post-tests were run using 
Minitab software, version 16.1.1.   
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Table 2.4. Preparation of liposome aggregates for 500 nM contamination study (all 
volumes in L) 
 HEPES 
buffer (25 
mM, pH 8) 
Liposomes 
(1.4 mM total 
lipid) 
MgSO4 
at 2 M 
Heparin (1 
µM 
concentration) 
Over-sulfated 
contaminant 
Heparin only 122 50 6 178 
-- 
0.5 mol% 
contamination 
114 50 6 177.11 
8.9 (100 nM) 
1.0 mol% 
contamination 
122 50 6 176.2 
1.78 (1 µM) 
2.5 mol% 
contamination 
122 50 6 173.6 
4.45 (1 µM) 
5.0 mol% 
contamination 
122 50 6 169.1 
8.9 (1 µM) 
10.0 mol% 
contamination 
122 50 6 160.2 
17.8 (1 µM) 
15.0 mol% 
contamination 
122 50 6 151.3 
26.7 (1 µM) 
20.0 mol% 
contamination 
122 50 6 142.4 
35.6 (1 µM) 
30.0 mol% 
contamination 
122 50 6 124.6 
53.4 (1 µM) 
 
Results and discussion 
In our previous work, we have demonstrated that phosphocholine liposomes having either 
the pyranine lipid or the lissamine-rhodamine lipid present in the bilayer at 1 mol% were able to 
distinguish between different GAG species in solution
21
.  In these studies, we have found the 
optimal liposomes for GAG discrimination contain the pyranine or the rhodamine lipid (Figure 
2.1 shows structures of these lipids); however preliminary studies demonstrated that liposomes 
containing the pyranine head group tend to aggregate in the presence of excess of divalent 
cations (i.e., in the absence of GAG; data not shown).  Based on these prior results, we prepared 
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) liposomes incorporating 1 mol% of 
1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl; 
rhodamine lipid), as well as 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) liposomes 
38 
 
incorporating 1 mol% rhodamine lipid for use in these studies.  We employed transmission 
electron microscopy (TEM) and dynamic light scattering (DLS) to evaluate the relative diameter 
differences between aggregates produced by different GAGs.  Changes in diameter and zeta 
potential in the presence of different GAGs were also evaluated.  We used DLS and zeta 
potential changes to determine if there are any variations upon contamination of heparin with 
over-sulfated GAGs.    Inclusion of the fluorophore in the liposomal bilayer was originally 
intended for study of fluctuations in fluorescence emission intensity as a function of the 
aggregation phenomenon.  However, due to non-uniformity of the liposomal solution upon 
aggregation, fluorescence studies produced very variable results, and were thus removed from 
this study. 
 
Figure 2.1.  Structures of rhodamine (A) and pyranine (B) lipids.  
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Preparation of liposomes:  We have previously shown that 100 nm diameter liposomes 
composed of 99 mol% POPC and 1 mol% fluorophore-conjugated lipid (either pyranine, 
rhodamine, or dansyl) are able to discriminate between various GAGs
21
.  Although these 
liposomes undergo modulations in fluorescence intensity in the presence of GAGs only, we wish 
to utilize the tendency of these liposomes to undergo rapid changes in the aggregate diameter and 
zeta potential in the presence of GAG and divalent cations to develop a rapid screen for these 
contaminants.  To achieve this, we have chosen Mg
2+
 as a flocculating agent
22
, and have 
produced POPC liposomes of three diameters (50, 200, and 550 nm) and aggregated each of 
these in the presence of three concentrations (50, 170, and 500 nM) of each GAG of interest: 
heparin, over-sulfated heparin (OSH), over-sulfated chondroitin sulfate (OSCS), and over-
sulfated dermatan sulfate (OSD). We demonstrate that high concentrations of Mg
2+
 aggregate 
liposomes in the presence of GAG, but not in the absence of GAG (as shown in Tables 2.5 and 
2.6).  
Mechanistic studies--liposomes selectively aggregate upon binding of different GAG 
species when Mg
2+
 is present, and liposome-GAG interactions influence the zeta potentials 
and diameters of overall assembly:  Kim and Nishida had proposed that the divalent cation 
(Mg
2+
 in our case) form bridges between the negative phosphate groups of the phospholipid head 
groups
5
. This interaction shields the incoming GAGs from the negative charges on liposome 
surface, allowing them to bind to the positively charged choline
5
, leading to the formation of 
aggregates (see Figure 2.2).   
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Figure 2.2.  The addition of Mg
2+
 allows liposomes to form strong  
interactions with heparin/contaminants (C), resulting in liposome  
aggregates (D). 
 
To study this effect, we used both DSPC-rhodamine liposomes and POPC-rhodamine 
liposomes (200 nm diameter) in the presence of Mg
2+
 only, in the presence of each GAG only 
(no Mg
2+
), and finally in the presence of both GAG and Mg
2+
 (GAG concentration was held 
constant at 170 nM).  Both diameters and zeta potentials of the resulting aggregates were 
measured.  Results of these studies are as shown in Tables 2.5 and 2.6.   
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Table 2.5.  Diameters and zeta potentials of POPC-containing liposomes in 
the presence of GAG, with and without Mg
2+
 
Formulation 
Zeta potential  
(mV) 
Diameter (nm) 
Liposomes only -13.3 + 0.78 183.1 + 8.01 
Liposomes + Heparin  -11.6 + 1.16 177.0 + 3.94 
Liposomes + OSH -12.1 + 0.80 
174.4 + 6.35 
Liposomes + OSCS -12.3 + 0.37 
186.8 + 3.2 
Liposomes + OSD -12.2 + 0.41 
173.5 + 4.45 
Liposomes + Mg
2+
 4.4 + 0.61 179.5 + 1.58 
Liposomes + Mg
2+ 
+ Heparin  4.6 + 0.58 540.8 + 50.49 
Liposomes + Mg
2+ 
+ OSH 4.7 + 0.75 773.9 + 78.54 
Liposomes + Mg
2+ 
+ OSCS 3.2 + 0.97 2098.6 + 192.87 
Liposomes + Mg
2+ 
+ OSD 3.7 + 0.80 3325.8 + 543.79 
 
Table 2.6.  Diameters and zeta potentials of DSPC-containing liposomes in 
the presence of GAG, with and without Mg
2+
. 
Formulation 
Zeta potential  
(mV) 
Diameter (nm) 
Liposomes only -11.8 + 0.28 254.9 + 90.97 
Liposomes + Heparin  -11.4 + 0.81 374.2 + 61.16 
Liposomes + OSH -11.9 + 0.44 
445.9 + 68.92 
Liposomes + OSCS -11.7 + 0.43 
429.4 + 36.72 
Liposomes + OSD -12.7 + 0.34 
426.6 + 58.89 
Liposomes + Mg
2+
 10.3 + 0.91 397.7 + 96.19 
Liposomes + Mg
2+ 
+ Heparin  6.7 + 1.11 2603 + 189.51 
Liposomes + Mg
2+ 
+ OSH 6.7 + 1.08 1873 + 162.66 
Liposomes + Mg
2+ 
+ OSCS -16.0 + 0.62 2483 + 200.76 
Liposomes + Mg
2+ 
+ OSD -2.7 + 0.67 3489 + 762.22 
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As the zeta potentials of both POPC and DSPC-containing liposomes do not appear to 
change significantly without the presence of Mg
2+
, we conclude that the GAGs alone do not bind 
to the surface of liposomes, as has been previously reported
4
.  However in contrast to previous 
studies
4
, we find that excess Mg
2+
 does result in liposomal charge inversion
23
, changing the zeta 
potential of the liposomes. It is likely that previous studies did not use divalent cations in 
sufficiently large excess to observe this effect.  Consistent with previous findings, we note a 
significant change in the zeta potential upon the addition of both Mg
2+
 and GAG in the presence 
of DSPC liposomes; however this effect is negligible for POPC liposomes.  Interesting to note is 
the drop in zeta potential of the DSPC aggregates to -16 mV in the presence of OSCS, 4 mV 
below that of the original liposomes.  This effect likely results from overcharging of the 
liposome surface, due to excess charge from the OSCS
23
.  Both liposomes experience significant 
changes in aggregate diameter in the presence of GAG and Mg
2+
, and these diameter changes 
appear to be dependent on the species of GAG present, particularly for POPC liposomes.  It must 
also be noted that previous studies by M. Krumbiegel and K. Arnold describe the measurement 
of zeta potential in the presence of liposomes aggregated by glycosaminoglycans, and they have 
found that this aggregation in no way interferes with the measurement of zeta potential
2
. 
Mechanistic studies—diameter and zeta potential of liposome aggregates reach 
saturation upon addition of sufficient concentrations of GAG: To determine how the 
aggregate hydrodynamic diameters and zeta potentials of both DSPC and POPC containing 
liposomes changed with increasing concentrations of each GAG, and to determine if there were 
any differences between GAGs at these concentrations, DSPC and POPC liposomes were 
incubated with heparin, over-sulfated chondroitin sulfate, over-sulfated dermatan sulfate, and 
over-sulfated heparin at eight concentrations (100 nM, 500 nM, 1 M, 10 M, 50 M, 100 M, 
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250 M, and 500 M).  Results are summarized in Figure 2.3 below; each data point is the 
average of three collected aggregate diameters or zeta potential measurements.  We note that 
some of the diameter measurements are outside the range which the Zetasizer Nano may 
accurately measure (5 x 10
3
 nm diameter), however the purpose of these experiments was to 
investigate whether each species of GAG caused the eventual saturation of both aggregate 
diameters and zeta potentials, and if so above what concentration does this saturation take place.  
Measurements are of interest in terms of general trend only.  Notable are the progression of 
aggregate diameters from small to quite large and then to small again for both DSPC and POPC 
containing liposomes, as concentration increases.  This is consistent with theoretical analysis of  
McClements
24
 and Guzey
25
, according to which  below a specific critical concentration of 
charged polymers (e.g., GAGs), the surface of the colloid particles (liposomes) will be 
incompletely covered by the polymer, resulting in an imbalance between attractive and repulsive 
forces acting on the colloidal particles.  Below this critical concentration, these imbalances will 
allow sections of liposome surface coated with GAG to attract sections of neighboring liposomes 
which have not been so coated, resulting in aggregate formation. Above this critical 
concentration however, the surfaces of the colloidal particles will become saturated as the 
charged polymer forms a continuous coat on the surface, and allows the repulsive forces between 
the colloid particles in solution to become re-balanced, preventing significant aggregation.  
McClements
24
 also notes that at concentrations much higher than the critical concentration may 
cause “depletion flocculation” due to excesses of polymer electrolyte in solution, which may be 
sufficient to overcome the repulsive forces between colloid particles.  This depletion flocculation 
may be one explanation for the sudden increase in diameter of the POPC liposomes in presence 
of 500 M over-sulfated heparin.   
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Figure 2.3.  DSPC and POPC aggregate diameters and zeta potentials with increasing GAG 
concentration.  Average aggregate diameters of DSPC liposome aggregates (A) and POPC 
liposomes (B); and average zeta potentials of DSPC liposome aggregates (C) and POPC 
liposomes (D) in the presence of increasing concentrations of heparin (black squares), over-
sulfated chondroitin sulfate (blue triangles), over-sulfated dermatan sulfate (red circles), and 
over-sulfated heparin (green upside-down triangles). 
 
For the DSPC containing liposomes, as the aggregate diameter becomes saturated, the 
zeta potential becomes likewise saturated (at high GAG concentration), and does not change 
appreciably at higher concentrations.  For the POPC containing liposomes however, there is a 
tendency for the zeta potential to reach a minimum, and then return to smaller absolute values at 
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higher concentrations.  This difference is clearly due to the difference in composition of the fatty 
acid tails of the liposomal lipids. In the case of DSPC, both tails are constituted of saturated 
(stearic acid) and thus they will pack more efficiently (vis a vis the palmitoyl and oleyl tails of 
POPC) within the lipid phase. These differences will impart greater rigidity to the head groups of 
the DSPC liposomes, and thus will allow homogeneous distribution of GAG induced aggregates 
of the liposomes.  The above feature is unlikely to prevail in the case of POPC liposomes.  It is 
worth noting that other studies involving changes in the liposome’s zeta potential upon addition 
of GAGs and divalent cations were focused on lipid bilayers, harboring saturated lipids (DMPC, 
DLPC, and egg lecithin)
2,4
, and these studies produced zeta potential results similar to our DSPC 
liposomes.  However, irrespective of the underlying physical forces responsible for our observed 
experimental data of Figure 2.2, it is evident that POPC and DSPC formulated liposomes elicit 
marked differences in their aggregational states and zeta potentials as a function of different 
types of GAGs. Whether or not such features are intimately involved in discriminatory changes 
in the liposome’s resident fluorescence probes21 as a function of different types of GAGs are 
currently being investigated in our laboratory, and we will report these findings subsequently.  
TEM images demonstrate differential aggregation of liposomes in the presence of 
different GAG species: The diameters of the POPC liposomes and DSPC liposomes in the 
presence of Mg
2+
 only were compared with those in the presence of heparin, over-sulfated 
chondroitin sulfate, over-sulfated dermatan sulfate, and over-sulfated heparin.  Figure 2.4 
presents the TEM images of the POPC liposomes in the presence of Mg
2+
 alone (panel A) and in 
the presence of Mg
2+
 and different GAG species. Figure 2.5 presents the corresponding TEM 
images involving DSPC liposomes. In each figure, panels A-E are images of liposomes 
magnified 5,000 times, and panel F is an image of one OSCS aggregate magnified 25,000 to 
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show detail of the stacked liposomes.  The TEM images of Figures 3 and 4 clearly reveal that the 
liposomes are aggregated in the presence of Mg
2+
 and different GAG species, and such 
aggregates are asymmetrical and polydisperse.  However, notable in these TEM images is the 
presence of considerably larger aggregates in the presence of over-sulfated GAGs as compared 
to those observed in the presence of heparin.  Also notable is the apparent size in these images; it 
is evident that the liposomes and aggregates have collapsed during the preparation of the 
samples.  It is therefore necessary to consider these sizes as relative; aggregate images should 
only be compared with images of the liposomes in the presence of Mg
2+
 only. 
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Figure 2.4. TEM images of POPC liposomes in presence of different GAGs. TEM images of 
POPC liposomes with Mg
2+
 only (A): red arrows denote individual liposomes), and aggregated 
in the presence of heparin (B), over-sulfated chondroitin sulfate (C), over-sulfated dermatan 
sulfate (D), and over-sulfated heparin (E) magnified 5,000x.  Notable is the increase in average 
size of the aggregates of over-sulfated GAGs over heparin, as well as the polydispersity of these 
aggregates.  Shown also is an image of liposomes aggregated with over-sulfated chondroitin 
sulfate magnified 25,000x (F).  Clearly shown are the clustered bilayers in one section of the 
aggregate, denoted by the red arrows. 
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Figure 2.5. TEM images of DSPC liposomes in presence of different GAGs. TEM images of 
DSPC liposomes with Mg
2+
 only (A), and aggregated in the presence of heparin (B), over-
sulfated chondroitin sulfate (C), over-sulfated dermatan sulfate (D), and over-sulfated heparin 
(E) magnified 5,000x.  Notable is the the polydispersity of these aggregates.  Shown also is an 
image of liposomes aggregated with over-sulfated chondroitin sulfate magnified 25,000x (F).  
Visible are the closely associated liposomes within a single aggregate. 
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  Differential scanning calorimetry demonstrates intrinsic and differential stability of 
liposomes upon binding of GAGs to liposomes:  Having established that the liposomes are 
aggregated in the presence of both Mg
2+
 and different GAG species, it was of interest to 
investigate whether the above “effectors” modulated the intrinsic stability of liposomes. To 
probe this, we performed DSC studies for melting of DSPC liposomes in the presence of Mg
2+
 
and two concentrations (i.e., 1 µM and at 250 µM) of each different GAG species. The DSC 
endotherms reveal that the presence of Mg
2+
 and GAGs influence both the melting temperature 
(Tm value) of the liposomes as well as the area under the peaks (measure of the enthalpic changes 
between native and denatured/melted forms of the liposomes; see Figure 2.6).  The observed 
shifting of the 250 µM trace to a lower relative heat rate reflects the increase of dissolved solutes 
over the control
26
, and the widening and flattening of the DSC trace with increasing GAG 
concentration, accompanied by a rightward shift in Tm, indicates that structural changes are 
taking place within the bilayers of the liposomes (increased Tm), and that these changes are 
dispersed somewhat unevenly within the “population” of the liposomes (widening and flattening 
of the Tm peak)
26
.  To our further interest, we observed that the second DSC scan (performed 
after cooling the heated sample after the first scan) yielded essentially identical Tm values in the 
presence of different  GAG species, albeit the enthalpic changes were slightly decreased (data 
not shown). This suggests that there is a marked reversibility in the organizational states of the 
liposomes, and such feature is intrinsic to the nature of the GAG species. Table 2.7 summarizes 
the Tm values and enthalpic changes under our selected experimental conditions.  A perusal of 
the data of Table 2.6 reveals that among different GAGs used herein, heparin and oversulfated 
heparin exhibit the least and most stabilizing influence on the liposomes as evident by their 
corresponding enthalpic changes. 
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Figure 2.6. Differential scanning calorimetry of DSPC liposomes with GAGs. DSC traces of 
DSPC liposomes with heparin (A), over-sulfated chondroitin sulfate (B), over-sulfated dermatan 
sulfate (C), and over-sulfated heparin (D): liposomes only (black trace), GAG at 1 M (red 
trace), GAG at 250 M  (blue trace).   
 
We conclude from these studies that binding of GAGs and Mg
2+
 to the liposomal bilayer 
causes the liposomal assembly  to become more stable, and thus requires more heat energy 
(enthalpic changes) to bring it to the fully disorganized (melted) states with concomitant increase 
in the transition temperature.  We believe the above feature is due to the intercalation of the 
GAGs between the individual phosphocholine molecules, thus forcing the exclusion of 
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intervening water molecules and thus allowing the liposomal lipids to pack more efficiently in 
their native states.  
Table 2.7.  Heat required for liposome melting (J) 
GAG Liposomes only 1 M 250 M 
Heparin 1709.1 2814.9 2887.1 
OSCS 1709.1 3338.2 3367.5 
OSD 1709.1 3693.2 2793.5 
OSH 1709.1 3653.9 3853.4 
 
Mechanistic studies--there is an inverse relationship between the percent change of 
aggregate diameter and the percent change of aggregate zeta potential as the concentration 
of GAG increases, independent of liposome diameter:  For studies comparing the relative 
contribution of liposome diameter and GAG concentration to the overall average diameter and 
zeta potential changes of the resulting aggregates, only POPC liposomes were used.  This is due 
to the high variability of the DSPC liposomes’ diameters, which is clear from results shown in 
Table 2.6 (the standard deviation for the diameter of these liposomes alone as measure by DLS is 
36% of their diameter).  Additionally, DLS shows the presence of both very large (>1000 nm) 
and very small (<50 nm) particles in the DSPC liposome solution.  Due to this difficulty in 
controlling the liposome diameter, DSPC liposomes have been excluded from this, as well as the 
contamination studies.   
As one considers the percent change of each over-sulfated contaminant relative to heparin 
at each concentration, while holding the diameter of the liposomes constant, an interesting 
pattern emerges: there appears to be an inverse relationship between the percent change in 
aggregate diameters, and the percent change in aggregate zeta potential (i.e.—as the percent 
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change in diameter goes down with increasing GAG concentration, the percent change in zeta 
potential becomes greater with increasing GAG concentration).  These results are summarized in 
Figure 2.7.  Notable from this figure is that at 50 nM concentration (represented by a black trace 
with black squares), OSCS always produces the greatest change in aggregate diameter, 
regardless of the liposomes’ starting diameter.  At 170 nM GAG, OSD causes the greatest 
changes in aggregate diameter, and at 500 nM GAG results depend on the starting liposome 
diameter.  Reasons for this are unclear, and will require further investigation.  However it is 
obvious from these results that as GAG concentration increases, overall percent change 
decreases.   Results for percent change in aggregate zeta potential are also very consistent for 
liposomes of all diameters tested:  as GAG concentration increases, the magnitude of percent 
change in aggregate zeta potential also increases.  We hypothesize the mechanism for this may 
be due to differences in the percent overall coverage of the liposome surface by the GAG.  When 
the concentration of GAG in solution is relatively low relative to the total lipid concentration in 
solution (~200 nM), the liposomal surface is covered with GAG to a lesser extent, resulting in 
greater imbalance between the attractive and repulsive colloidal forces.  As such, the number of 
liposomes which form aggregates will be dependent on the charge density of the GAG present on 
the liposome surface, as well as the surface area between oppositely charged sections of each 
bilayer (a function both of liposome diameters and the percent of surface area covered).  
However, as the concentration of GAG in solution increases, the surface of each liposome 
bilayer will be covered to a greater extent, which will not only begin to re-balance the repulsive 
forces between them in solution, but it will also reduce the amount of available surface area for 
aggregation between liposomes.  This will reduce the percent change in the aggregate diameter 
(as fewer liposomes will be able to aggregate together), as well as increasing the change 
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observed in the zeta potentials (as a function of the amount and charge density of the GAG 
bound).  Studies to confirm this mechanism are currently being undertaken. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.7.  Percent changes for 50 nm diameter liposomes (A, B), 200 nm liposomes (C, D), 
and 500 nm liposomes (E, F).  Shown are percent changes in aggregate diameter (A, C, E) and 
percent changes in aggregate zeta potential (B, D, F).  Concentrations used for this study are 50 
nM (black squares), 170 nM (red circles), and 500 nM (blue triangles).   
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Contamination studies demonstrate that changes in diameter and zeta potential of 
POPC liposomes can distinguish small changes in GAG composition:  The insights gained 
from the previous studies were employed to probe whether the presence of low concentrations of 
over-sulfated contaminants in a heparin sample could be detected using DLS and zeta potential 
measurements of liposomal aggregates.  We chose to incubate 200 nm diameter liposomes with 
170 nM contaminated heparin (produced the greatest percent changes in diameter), and 500 nm 
diameter liposomes with 500 nM contaminated heparin (produced the greatest percent changes in 
zeta potential).  Heparin samples in 2008 were found by Beyer, et al, to be contaminated in the 
range of 0.5% to 28% by weight
9
.  As such, for both of these liposome/GAG concentration 
combinations, eight contamination levels were prepared: 0.5, 1.0, 2.5, 5, 10, 15, 20, and 30 mol% 
contaminations with each over-sulfated contaminant.  Each combination was measured for 
changes in aggregate diameter and zeta potential by DLS.   
Analysis of variance (α = 0.05) was conducted for each of these sets of data (see 
statistical results in Appendix B).  Included in this analysis is a comparison of means for each 
contamination level against heparin alone using Dunnett’s method for pairwise comparisons27. 
This method allows us to compare each contamination level to the control (heparin only) while 
controlling the family-wise error of all comparisons together to 0.05.  Results for both 200 nm 
and 500 nm diameter liposomes indicate that OSH could not be consistently detected, and thus 
will be eliminated from further discussion. 
Results for OSCS and OSD are far more promising.  Analysis of variance indicates that 
for the 200 nm liposomes, changes in average aggregate diameter could detect contamination by 
OSCS at concentrations from 5 mol% to 30 mol%, and OSD contamination from concentrations 
of 10 mol% to 30 mol%.  Changes in aggregate zeta potential could not consistently detect 
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contamination.  Results for the 500 nm diameter liposomes indicate detection of OSCS 
contamination at concentrations from 1 mol% through 30 mol% by changes in zeta potential, and 
from 2.5 mol% to 30 mol% by changes in aggregate diameter.  OSD could be detected by this 
method from 10 mol% to 30 mol% by changes in zeta potential, and from 0.5 mol% to 30 mol% 
by changes in aggregate diameter. (For detailed statistical results please see Appendix B).  If we 
consider percent heparin contamination by weight, the lowest contamination level we can detect 
using these methods is approximately 1.6% by weight of OSD, and 2.2% by weight of OSCS, 
making it an attractive screening tool for heparin intended for clinical use.  These calculations 
are based on the estimated molecular weights of heparin, over-sulfated chondroitin sulfate, and 
over-sulfated dermatan sulfate, summarized in Table 2.8 below. 
Table 2.8.  Molecular 
weight of GAGs (g/mol) 
GAG Liposomes only 
Heparin 13,500 
OSCS 29,560 
OSD 42,529 
 
It must be stated that despite the relative consistency and significance of the DLS 
diameter measurements, the presence of fluorescence, high polydispersity, and large 
precipitating particles in the sample lead us to favor the use of zeta potential for measurements of 
over-sulfated heparin contaminants, as these measurements are unaffected by any of the 
aforementioned concerns.  
A comparison of current methods used to detect heparin quality reported in 2011 by 
Alban, et al., has been very revealing.  The authors reported that while NMR and other 
spectroscopic methods are useable, other heparin mimetic may cause deviating results, and thus 
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accurate detection of OSCS in heparin will be in large part dependent on the skill of the 
individual running the tests, and only currently known heparin contaminants may be 
recognized
18
.  Additionally, the PT and aPTT, while they are able to detect overall heparin 
quality, cannot actually detect contamination, and have an LOD of 3%
18
.  Further, it must be 
recognized that no reported adverse effects were observed from enexoparin contaminated with 
up to 7% OSCS
15
.  Based on this, the analysis by Alban and Beyer of original contaminated 
samples
9,18
, and the above statistical analysis of our data, we believe that zeta potential 
measurements combined with DLS diameter measurements of POPC based liposomes incubated 
with heparin samples at 170/500 nM and excess Mg
2+
 may be a rapid and economical initial 
screen for contamination in these samples. 
Conclusions 
We have demonstrated that liposomes containing 1 mol% lissamine-rhodamine lipid form 
aggregates of varying diameters and zeta potentials depending on the species and concentration 
of GAG present.  This has been verified by TEM studies.  We have shown that organizational 
states of the liposome bilayers are influenced by the presence of GAG and excess Mg
2+
, resulting 
in a stabilizing effect, and the magnitude of this effect is also dependent on GAG species and 
concentration present.  Additionally, there is an inverse relationship between the percent change 
of aggregate diameter and percent change of aggregate zeta potential, as a function of GAG 
concentration in solution.  Finally, the presence of small concentrations of over-sulfated 
contaminants in heparin samples cause statistically significant variations in the average 
aggregate diameter and zeta potential POPC liposomes.  Significant variations of POPC 
liposome aggregate zeta potentials enables detection of over-sulfated chondroitin sulfate and 
over-sulfated dermatan sulfate at 1 mol% and 0.5 mol % (2.2% w/w and 1.6% w/w, 
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respectively).  Based on the work of Bayer, the use of this method would have been able to 
detect the contaminants in the majority of the original heparin samples which caused allergic 
reactions and deaths of patients in 2007 and 2008
9
.  These results offer insight into the potential 
of these interactions for a rapid and economical screen for the presence of over-sulfated 
contaminants in heparin or other drugs.   
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PAPER 3. URINARY CONCENTRATIONS OF ADAM 12 FROM BREAST CANCER 
PATIENTS PRE- AND POST-SURGERY VS. CANCER-FREE CONTROLS: A CLINICAL 
STUDY FOR BIOMARKER VALIDATION 
Abstract 
The ADAMs (A Disintegrin and Metalloproteinases) are a family of 35 multi-domain, 
zinc-dependent metalloproteinase enzymes.  ADAM isozyme 12 (ADAM 12) has been 
previously associated with the onset and progression of breast cancer, and elevated levels of the 
secreted form (ADAM 12-S) have been previously found in the urine of breast cancer patients.  
Aims of the current study are: 1) establish the viability of urinary ADAM 12 as a screening 
marker for breast cancer, and 2) explore the effects of surgical tumor removal on the levels of 
urinary ADAM 12.  A total of 68 patients have been recruited for this study, including 37 
patients diagnosed with cancer, and 31 age-matched controls. Commercially available ELISA 
kits for ADAM 12 were used to quantify the presence and concentration of this enzyme in the 
urine from cancer patients with ductal carcinoma in situ (DCIS) and invasive breast cancer (IBC) 
both prior to any treatment and approximately two weeks following surgery, as well as from 
controls.  We find no statistically significant differences between the concentrations of ADAM 
12 in the urine of breast cancer patients prior to treatment and that of their age-matched controls; 
however the concentration of ADAM 12, both alone and as a function of urine total protein, are 
significantly elevated following surgery (p < 0.0001).  Patients who underwent a mastectomy 
have significantly higher urinary ADAM 12 concentrations than those who underwent a 
lumpectomy (significant at p = 0.0271). Based on these results, a screen for urinary ADAM 12 is 
unlikely to prove useful for breast cancer diagnosis. 
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Introduction 
Breast cancer is currently the second leading cause of cancer deaths among women in the 
United States  (second only to lung cancer), and it is now estimated that in the U.S. one in eight 
women will be diagnosed with breast cancer during her lifetime
1
.  However, if breast cancer is 
detected during its earlier stages, the 5-year survival rate may be as high as 93%
**
 (at stage 0); 
when detected at stage IIIB and later, 5-year survival rate drops below 50%
2
, making early 
detection of breast cancer essential for favorable prognosis.  Blood-based antigens currently 
measured to screen for breast cancer include (but are not limited to) cancer antigen 15-3 and 
27.29 (CA15-3, CA27.29), carcinoembryonic antigen (CEA), and HER2/neu
3,4
; however these 
show little potential for early detection
5
. Recent studies have begun exploring the potential of 
urinary biomarkers for breast cancer detection
6,7
, and among those studied are the ADAM 
proteases, particularly ADAM 12.   
The ADAMs (A Disintegrin and Metalloproteinases) are a family of 35 multi-domain, 
zinc-dependent metalloproteinase enzymes.  ADAMs are usually membrane bound (although 
some isozymes have secreted forms, including ADAM-9
8
, -10
9
, -12
10
 and -28
11
), and their 
physiological roles include extracellular matrix restructuring
12-14
, to cell adhesion
15-17
, to cell-
surface protein processing
18-20
.  ADAM 12, which is transcribed as both a membrane bound and 
a secreted form, has roles in cell adhesion and matrix restructuring during cell differentiation
15-
17,21
, and also has regulatory functions
22
 in healthy tissues.  ADAM 12 has also been associated 
with development and progression of a number of disease states, including arthritis
23
, cardiac 
hypertrophy
24
, liver fibrogenesis
25
, and various cancers, including bladder 
26
, lung 
27
, brain 
28
 and 
breast
29
.   
                                                 
**
 These numbers reflect death from all causes.   
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One study in 2004 indicated a strong correlation between excretion of urinary ADAM 12-
S (the short, secreted form of the enzyme), and breast cancer status and stage
29
.  This report 
concluded that patients with ductal carcinoma in situ (DCIS), invasive breast cancer (IBC), and 
metastatic breast cancer had significantly higher levels of ADAM 12-S present in their urine than 
controls (i.e. patients with “no discernible disease”)29.  The report further concluded that only 
15% of the control subjects had detectable levels of ADAM 12 present in their urine, while 82%, 
86%, and 85% of patients with DCIS, IBC and metastatic disease, respectively, were positive for 
the presence of ADAM 12-S
29
.  These results strongly suggest that a urine screen for the 
presence of ADAM 12 would prove especially useful for the diagnosis of breast cancers, stage 
DCIS and later.   
The aims of the current study are twofold: 1) establish the viability of urinary ADAM 12 
as a screening marker for breast cancer, and 2) explore the effects of surgical tumor removal on 
the levels of urinary ADAM 12.  Our primary objective is to establish a simple, practical 
screening test for the early detection of breast cancer.  As such, we have chosen to utilize 
commercially available ELISA kits for urinary ADAM 12 screening: we reason that they are a 
well accepted technology, which will provide reliable, reproducible results in a clinic setting. 
Materials and methods 
Ethics review and approval: This study was conducted in compliance with the Helsinki 
Declaration. The protocol, informed consent form, and laboratory manuals for this study were 
reviewed and approved by the Sanford Health Institutional Review Board in compliance with its 
Federalwide Assurance (#00016819).  All patients’ participation was voluntary, and all enrolled 
participants were given the right to refuse or exit the study at any time.  Participants’ were given 
a unique study number; and therefore their specimens and related medical information were de-
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identified.  Participant’s study related medical record information was protected in accordance 
with HIPAA regulation.  
Materials:  Coomasie Blue (Bradford) Assay Kit was obtained from Thermo Scientific 
(Rockford, IL), and 96-well polystyrene plates for this assay were obtained from Greiner Bio-
One (Monroe, NC).  ADAM 12 enzyme linked immunosorbent assay (ELISA) kits obtained 
from R&D Systems (Minneapolis, MN).  All supplies used without any further modification. 
Patient recruitment:  Study participants were screened during their visit either to the 
Sanford Breast Clinic and/or breast surgeon consultation visit by their treatment provider.  If 
they wished to participate in the study, the clinical research coordinator met with them to discuss 
and/or complete the Informed Consent Form (ICF) document and process.  After consent was 
obtained, the coordinator collected the pre-surgery or control urine sample, and informed those 
participants with breast cancer of the need to leave a second sample at a follow-up visit after 
their surgery.  Control patients were matched for age and co-morbidities.  They were selected 
from Sanford Medical Center Breast Clinic or other clinics.  If they had benign and non 
interventional breast findings they were approached at their clinic visit about participation in the 
study and appropriately consented.  Controls were consented using the same ICF document and 
process as breast cancer subjects.   
Inclusion criteria:  
 Females age 21 years of age or older 
 Recent diagnosis of breast cancer 
 No previous diagnosis of cancer, excepting non-melanoma skin cancer. 
 Treatment naïve (i.e.no chemotherapy or radiation therapy prior to surgery for this 
breast cancer diagnosis) 
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Exclusion criteria: 
 Pregnancy 
 Advanced stage breast cancer disease (i.e.—stage 4 cancer with multiple 
metastasis) 
Age-matched controls were females with no positive history of breast cancer or other previous 
diagnosed cancers, excluding non-melanoma skin cancer.  All patients were recruited for study 
from the Sanford Medical Breast Clinics, and were consented in accordance with institutional 
regulatory board guidelines.  All breast cancer patients had surgery as their initial treatment.  The 
surgeries involved either a lumpectomy or a mastectomy for local control of their cancer; and in 
most cases included either an axillary sentinel lymph node dissection.  When indicated a level I 
and II axillary lymph node dissection was done as part of the same procedure based on frozen 
section evaluation on the sentinel lymph nodes.  The decision of surgery options was made after 
multidisciplinary treatment planning, consultation with the patients, and followed National 
Cancer Cooperative Network (NCCN) guidelines.  
Urine collection and processing:  Following consent, patients and controls were brought 
to a private area and asked to leave a urine sample.  Immediately following collection, the urine 
was well mixed, and ten milliliters (10 mL) was aliquoted into a sterile, 10 mL screw cap test 
tube, and labeled with the patients de-identified information only; available information includes 
only patient age, stage of cancer, tumor size and co-morbidities.  These samples were 
immediately placed upright in a -80ºC freezer for storage.  Recruited breast cancer patients 
provided two samples of urine, one just following diagnosis, and a second approximately two 
weeks following surgery to remove the tumor mass (all patients recruited for this study were 
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scheduled for surgery).  Controls have provided one sample only.  Upon collection of 20 
samples, tubes were transported to North Dakota State University on dry ice for testing.   
Prior to testing, samples were thawed on ice and centrifuged at 200 rcf for 15 minutes to 
remove any particulates. The resulting supernatant was diluted 1:5 in one of two buffers: for the 
Bradford assay, 50 mM Tris at pH 8 was used, and for ELISA the calibrator diluent provided 
with the kit was used, as per the manufacturer’s suggestion.  Preliminary data demonstrated the 
necessity of dilution such that the ADAM 12 concentration in the patient samples would fit 
within the standard curve of the ADAM 12 ELISA. 
Bradford assay:  Manufacturer’s instructions for the “micro microplate procedure” 
obtained with the kit were followed regarding volumes of samples, standards, and assay reagent.  
Bovine serum albumin was provided with the kit, and was used to produce the standard curve.  
The 2 mg/mL albumin standard was diluted in 50 mM Tris buffer (pH 8) to produce a standard 
curve ranging from zero µg/mL to 100 µg/mL.  Twenty patient and/or control urine samples 
diluted 1:5 (see section on urine collection and processing) were loaded into four wells each of a 
96-well standard clear bottom polystyrene plate, 150 µL per well.  Standard samples were also 
loaded, two wells each sample, 150 µL per well.  Bradford assay reagent provided was loaded 
into each well, 150 µL per well, and the plate was mixed on a shaker for 10 seconds, followed by 
incubation at room temperature for 10 minutes.  Reading of plate absorbance, production of the 
standard curve and analysis of the samples was performed according to manufacturer’s 
instructions.   
ELISA:  Twenty patient and/or control urine samples diluted 1:5 (see section on urine 
collection and processing) were loaded into four wells each of the provided 96-well plate of a 
commercially available ELISA kit.  Standard samples were also loaded, two wells each.  
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Manufacturer’s instructions were followed for production of standard curve and analysis of 
samples. 
Statistical analysis:  Groups were compared using nonparametric Mann-Whitney test (α 
= 0.05). Analysis was performed using Minitab (v. 16.1.1). 
Results 
A total of 37 patients with the diagnosis of breast cancer and 31 age matched control 
patents were recruited into the study. Based on the data collected, no significant differences exist 
between the urinary ADAM 12 concentrations of the control patients and the cancer patients 
prior to their surgery.  The urinary concentration of ADAM 12 increased significantly following 
patient surgery (p < 0.0001), both in ng/mL and as a function of total urine protein.  Results are 
summarized in Table 3.1 and Figure 3.1 below.   
Table 3.1. Cancer patient group vs. control group 
 Cancer Group: 
Pre-surgery 
(n = 37) 
Cancer Group: 
Post-surgery 
(n = 35) 
Control group 
(n = 31) 
Age  Mean: 61 + 13 
Median: 60 
Mean: 61 + 12.4 
Median: 60 
Mean: 58 + 10.7 
Median: 58 
[ADAM 12] (ng/mL) Mean:  3.22 + 2.35 
Median: 2.52 
Mean: 18.3 + 17.0 
Median: 12.78 
Mean: 3.74 + 3.1 
Median: 2.85 
% Increase in ADAM 12 
Concentration Post-Surgery 
Mean:  3.2 + 2.4 
Median: 2.5 
Mean: 18.3 + 17.0 
Median: 12.8 
Mean: 3.74 + 3.1 
Median: 2.9 
Total protein (µg/mL) Mean: 59.8 + 54.5 
Median: 39.0 
Mean: 62.3 + 26.5 
Median: 62.8 
Mean: 79.6 + 75.3 
Median: 50.6 
ADAM 12 as % of total protein Mean: 0.009 + 0.012 
Median: 0.005 
Mean: 0.031 + 0.32 
Median: 0.017 
Mean: 0.007 + 0.007 
Median: 0.005 
Cancer group consists of DCIS (n = 10) and IBC (n = 27) diagnoses.   
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Figure 3.1.  Boxplots showing 
urinary ADAM 12-S levels in 
patient groups (pre- and post-
surgery) vs. control group. 
Concentration of ADAM 12-S 
denoted in ng/mL (A), total 
protein concentration (B), and 
ADAM 12 as a % of total protein 
(C) are shown for each respective 
group.  Circles above and below 
the box denote 99% and 1%, 
respectively; vertical bars denote 
10-90%; the box denotes 25-75%; 
the square in the middle of the 
box denotes the mean; and the 
horizontal bar denotes the median.  
* p = 0.049, ** p < 0.0001 
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The cancer patients recruited for this study consist of 10 women with a diagnosis of 
DCIS, and 27 women with a diagnosis of IBC (27% and 73% of the total group, respectively).  If 
we consider these as separate groups and compare these groups individually to the control group 
the results do not change, nor do the DCIS and IBC patients differ significantly from each other 
pre-surgery (see Figure 3.2).  The ADAM 12 concentration ranges, median changes in 
concentration, and median percent change from pre- to post-surgery are also consistent between 
the DCIS and IBC groups (see Table 3.2).  Significant elevation of urinary ADAM 12 does take 
place after patients have undergone surgery (overall p-value < 0.0001).   
Table 3.2. Ranges and median change of ADAM 12 concentration for controls and cancer 
patients (by stage) 
Stage Pre-surgery Post-surgery Median change Median % change 
Control 0--11.01 ng/mL NA NA NA 
DCIS 0.6--6.4 ng/mL 2.9--53.8 ng/mL 9.5 500.2% 
IBC 0.4--11.1 ng/mL 1.1--53.8 ng/mL 7.5 423.7% 
 
Results further suggest a link between the extent of patient surgery and urinary ADAM 
12 elevation.  Of the cancer patients recruited for this study, 29 of these underwent 
lumpectomies, and 9 underwent mastectomies (83% and 17% of the total group, respectively; 
two of the recruited patients failed to leave post-operative samples).  The concentration of 
ADAM 12 in the urine of mastectomy patients was significantly higher than that of lumpectomy 
patients (p = 0.0271); the median increase in ADAM 12 concentration for mastectomy patients 
was 14.7 ng/mL , versus 7.0 ng/mL for lumpectomy patients.  When considered as a percentage 
of total protein, the percent urinary ADAM 12 following a mastectomy versus that following a 
lumpectomy was significant at p = 0.0731.  There were no statistically significant differences 
between the total urine protein concentrations of these groups.  These results are summarized in  
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Figure 3.2.  Boxplots showing 
urinary ADAM 12-S 
concentration in ng/mL pre- and 
post- surgery for DCIS patients 
only (A), IBC patients only (B), 
and both DCIS and IBC patients 
pre-surgery (C) with comparison 
to the control group.  Circles 
above and below the box denote 
99% and 1%, respectively; vertical 
bars denote 10-90%; the box 
denotes 25-75%; the square in the 
middle of the box denotes the 
mean; and the horizontal bar 
denotes the median.  
* p = 0.0017, # p = 0.0005,           
** p < 0.0001 
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Figure 3.3.  Boxplots showing 
urinary ADAM 12-S levels in 
patients who underwent 
lumpectomies or mastectomies vs. 
control group. Concentration of 
ADAM 12-S denoted in ng/mL (A), 
total protein concentration (B), and 
ADAM 12 as a % of total protein (C) 
are shown for each respective group.  
Circles above and below the box 
denote 99% and 1%, respectively; 
vertical bars denote 10-90%; the box 
denotes 25-75%; the square in the 
middle of the box denotes the mean; 
and the horizontal bar denotes the 
median.  
+ p = 0.0271, ++ p = 0.0731, ** p < 
0.0001 
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Table 3.3 and Figure 3.3.  There were no significant differences between the urinary ADAM 12 
concentrations of lumpectomy and mastectomy patients prior to their surgeries (data not shown).   
Table 3.3. Ranges and median change of ADAM 12 concentration for lumpectomy 
patients vs. mastectomy patients (compared with controls) 
Surgery Pre-surgery Post-surgery Median change 
Median % 
change 
Control 0--11.0 ng/mL NA NA NA 
Lumpectomy 0.5--11.1 ng/mL 1.08--53.8 ng/mL 7.0 322.2% 
Mastectomy 0.4--7.0 ng/mL 6.44--53.8 ng/mL 14.7 764.5% 
 
Discussion 
Interestingly, these results appear to contradict those published in 2004 
29
; while these 
authors have concluded that patients with DCIS and IBC had significantly higher levels of 
ADAM 12 in their urine, our data shows no significant difference between the cancer and control 
groups.   
These results raise a number of interesting questions.  The observed elevation in ADAM 
12 following surgery is not surprising: many matrix metalloproteinase enzymes are upregulated 
during wound healing 
30
, and evidence suggests that ADAM 12 is involved in tissue remodeling 
31
, making it likely to undergo upregulation following surgical or other trauma to the tissues.  We 
also note a priori that many patients recruited for this study have co-morbidities which may 
affect levels of ADAM 12 (e.g. osteoarthritis 
23
, allergic rhinitis 
32
, and asthma 
32
), however these 
co-morbidities are well balanced between the cancer group and the control group, and based on 
our analysis they have had no significant effect on the concentrations of urinary ADAM 12.  The 
data also shows that some cancer and control patients having levels of ADAM 12 above the 
median did not have obvious comorbidities.  It remains to be determined under what 
circumstances members of a certain group could have significantly elevated levels of urinary 
ADAM 12 compared to members of another group, assuming these groups are age-matched.  
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Based on our observations, these circumstances could easily occur if the group having elevated 
urinary ADAM 12 had undergone surgery within four weeks of having been tested.  Further, as 
those patients with more advanced stages of cancer would be likely to have had more extensive 
surgery; it would follow that those patients with higher stage breast cancers would appear to 
have higher urinary ADAM 12 concentrations.  Other tissue trauma could also play a role, such 
as biopsies.  Further, had existing comorbidities not been balanced between the control and test 
groups, it is likely these may play a role in the elevation of urinary ADAM 12 levels in one 
group over another.   
Conclusions 
In conclusion, we find no significant difference between urinary ADAM 12 
concentrations in patients diagnosed with DCIS or IBC and their age-matched controls prior to 
any surgery or other therapeutic treatment.  Further, we find no significant differences in urinary 
ADAM 12 concentrations between DCIS patients and IBC patients either prior to or following 
surgical treatment.  Following surgical treatment, the concentrations of urinary ADAM 12 are 
elevated significantly over age-matched controls, and the degree of this increase depends upon 
the severity of the surgery. These results are in contrast to those published by another group in 
2004 
29
.   However, as a final consideration we note that in 2011, the same group (which 
concluded in 2004 that DCIS patients have significantly elevated urinary ADAM 12 vs. controls) 
has conducted another study (utilizing fluorescent metalloproteinase substrates) to 
simultaneously detect a number of matrix metalloproteinases (MMPs) and ADAMs (MMP-1, -2, 
-3, -8, -9,  and -13; ADAM-8, -9, -10, -12, and -17) in the urine of cancer patients and age-
matched controls.  This study concluded that no statistical difference exists between DCIS 
patients and age-matched controls when this fluorescence-based method is used 
33
.  Based on 
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these findings, it is unlikely that a screen for the presence of urinary ADAM 12 will become a 
viable method for the diagnosis of breast cancer.   
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FUTURE STUDIES 
Clinical investigation of sera from Alzheimer’s disease patients 
 In our previous studies it became evident that increases in the serum concentration of 
glycosaminoglycan from 26 nM to 48 nM (corresponding to those of a healthy individual and an 
Alzheimer’s disease patient, respectively, after dilution) may be distinguished by decreases in the 
fluorescence emission intensity from liposomes composed of 99 mol% POPC (1-palmitoyl-2-
oleoyl-sn-glycero-3-phosphocholine), and 1 mol% of a pyranine-containing lipid
1
.  These 
experiments were carried out using commercially available serum from healthy patients, and 
addition of chondroitin sulfate was made following dilution to simulate the serum of a patient 
afflicted with Alzheimer’s disease.  To further confirm this effect, and to verify the efficacy of 
this method for the accurate diagnosis of Alzheimer’s disease, it will be necessary to conduct a 
clinical study.  Briefly, such a study would recruit patients diagnosed with Alzheimer’s disease 
and age-matched controls (individuals with no cognitive impairment) from a local hospital, and 
patient consent would be obtained in accordance with the Institutional Review Board of Sanford 
Health.  Blood would be taken from each patient and control, and the serum separated from the 
cells and clotting factors.  This serum would then be diluted and combined with pyranine-
containing liposomes as in our previous study, and the extent of fluorescence emission intensity 
changes recorded.  Non-parametric Mann-Whitney tests would be used to make statistical 
comparisons between the control group and Alzheimer’s group.  As a means of gaining access to 
study participants, collaboration with Sanford Medical Center would be sought. 
Enzymatic digestion of heparin to increase OSCS/OSD detection sensitivity 
 Our previous studies indicate that contamination of heparin with over-sulfated 
chondroitin sulfate or over-sulfated dermatan sulfate may be detected by aggregation of POPC 
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liposomes containing 1 mol% of a lissamine-rhodamine-containing lipid
2
.  The lowest limit of 
detection of this method was found to be 1 mol% over-sulfated chondroitin sulfate and 0.5 mol% 
over-sulfated dermatan sulfate, when using liposomes with a diameter of 500 nm.  It may be 
possible to increase the sensitivity of this method by selectively digesting the heparin in solution 
using the enzyme Heparin Lyase I.  Heparin Lyase I selectively cleaves substrates having 2-O-
sulfated -L-idopyranosyluronic acid at the cleaved linkages3, and as such should selectively 
degrade heparin allowing the over-sulfated contaminants to remain in solution at approximately 
their original molecular weight.  The presence of these proportionately larger over-sulfated 
glycosaminoglycans in solution should result in the presence of large liposomal aggregates, 
whereas a solution of uncontaminated heparin should be fully digested, and thus should result in 
very little liposomal aggregation.  Heparin Lyase I is commercially available, as is heparin 
sulfate; over-sulfated glycosaminoglycan contaminants could be produced as in our previous 
studies.  Optimization studies would be conducted to determine appropriate amounts of enzyme 
to add to solutions of heparin and contaminant, as well as appropriate duration of the digest.  
Confirmation of the anticipated effect would be determined using dynamic light scattering, as in 
our previous studies.   
Continued monitoring of breast cancer patients following completion of chemotherapy  
 In our previous studies, we have concluded that there are no significant differences 
between the urinary ADAM 12 concentrations of breast cancer patients prior to surgical 
treatment and those of their age-matched controls (no cancer present).  We further conclude that 
urinary concentrations of ADAM 12 are elevated following patient surgery, and that this 
elevation is significantly greater for patients following a mastectomy than a lumpectomy (the 
greater the severity of the surgery, the greater the elevation of urinary ADAM 12).  To further 
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understand the role of wound healing and other inflammation processes on the elevation of 
urinary ADAM 12, we will collect an additional sample of urine from the cancer patient group 
following the completion of their chemotherapy treatments (if any).  These samples will be 
analyzed in the same way as previously obtained samples.  In addition, patient records will be 
monitored for the reappearance of cancer for five years following the completion of treatment; 
possible correlations between elevation of ADAM 12 following surgery and reappearance of 
cancer will be explored.  Any required approval by the Sanford Health Institutional Review 
Board will be sought prior to the commencement of any study. 
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APPENDIX A. SUPPLIMENTARY INFORMATION FROM PAPER 1 
Synthesis of pyranine containing lipid 
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Figure A1. Pyranine lipid synthesis. 
 
MW = 1329.61 g/mol 
λex = 390 nm; λem = 400-600 nm 
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Cascade Blue (4): Methyl ester derivative of cascade blue (1.28 g, 2.14 mmol) was 
dissolved in water (20 mL) and stirred with NaOH (0.086 g, 2.15 mmol) for 30 min at 60
0
 C. 
After cooling the reaction mixture, 100 µL of HCl was added. To this clear solution isopropanol 
(60 mL) was added to effect precipitation. The mixture was stirred for 20 minutes, filtered and 
dried to afford free flowing yellow powder (1.131 g, 91%). 
1
H NMR (400 MHz, CD3OD):   
5.07 (s, 2H), 8.33(s, 1H), 8.76 (d, 1H, J = 10 Hz,), 9.11(d, 1H, J = 10 Hz), 9.19-9.24 
(overlapping doublet, 2H, J = 10.8 Hz and  10 Hz ), 9.378 (s, 1H). 
13
C NMR (100 MHz, 
D2O):

Compound 6: To a stirred mixture of diamino propanoic acid, 2PTSA ethyl ester (5.12 
g, 10 mmol) and oleic acid (5.64 g, 20 mmol) in CHCl3 (150 mL) and DMF (50 mL), BOP (8.85 
g, 20 mmol) was added. The reaction mixture was stirred for 5 minutes and NMM (6.5 mL, 60 
mmol) was added dropwise. Overnight stirring at room temperature resulted in a clear reaction 
mixture. The reaction mixture was then diluted with 250 mL additional CHCl3, quenched with 
brine, and the organic phase was washed successively with brine, 5% citric acid and 5% 
NaHCO3 solution. Organic layer was dried on sodium sulfate and solvent evaporated under 
reduced pressure. Oily residue was purified by SiO2 column chromatography employing 3:1 to 
3:2 hexane ethyl acetate. (Rf  =  0.3 in 1:1 ethyl acetate/hexane) to obtain the  pure product as a 
colorless oil(4.6 g, 70%) 
1
H NMR (400 MHz, CDCl3): 0.83-0.87 (t, 6H, J = 6.8 Hz), 1.18-1.32 
(m, 43H), 1.56-1.61 (m, 4H), 1.94-2.01 (m, 8H), 2.11-2.3 (m, 4H), 3.58-3.62 (m, 2H), 4.15-4.21 
(m, 2H), 4.53-4.58 (m, 1H), 5.26-5.33 (m, 4H), 6.15-6.18 (m, 1H), 6.71 (d, 1H, J = 7.2 Hz). 
Bis oloeyl diaminopropanoic acid ethyl ester (3.6 g, 5.44 mmol) in CH2Cl2/MeOH (2:1, 45 mL) 
was treated with LiOH.H2O (0.458 g, 10.89 mmol) overnight at room temperature.  After 
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complete consumption of starting material the reaction was stopped and acidified to pH 2 with 
dilute HCl and solvent was evaporated under reduced pressure. The residue was taken into 
CH2Cl2 and was washed with water to remove LiCl. Drying of organic phase over sodium sulfate 
and solvent evaporation afforded clear liquid which slowly became waxy solid. This was used in 
the next step without further purification. Compound 6 was obtained in 90% yield (3.1 g). 
1
H 
NMR (400 MHz, CDCl3):  0.78-0.82 (distorted triplet, 6H, J = 7.2 and 6.8 Hz), 1.17-1.25 (m, 
40H), 1.47-1.54 (m, 4H), 1.89-1.94 (m, 8H), 2.06-2.25 (m, 4H), 3.28-3.34 (m, 1H), 3.51-3.55 
(dd, 1H, J = 4 Hz and J = 9.6 Hz), 4.12-4.14 (q, 1H), 5.23-5.27 (m, 4H). 
Lipid 1: Following a similar protocol as above, compound 6 (3.6 g, 5.696 mmol) was 
conjugated with the mono BOC protected linker (1.447 g, 5.98 mmol) by employing BOP (2.646 
g, 5.98 mmol) and NMM (1.876 mL, 17.08 mmol) in chloroform (100 mL). After work-up and 
solvent evaporation it was purified by chromatography with CH2Cl2/MeOH (Rf = 0.3 in 5% 
methanol in CH2Cl2, iodine active).  Pure product obtained 4.1 g (yield: 84%). 
1
H NMR (400 
MHz, CDCl3): 0.83-0.87 (distorted triplet, 6H, J = 7.2 and 6.8 Hz), 1.2-1.38 (m, 40H), 1.41 (s, 
9H), 1.54-1.62 (m, 4H), 1.95-1.99 (m, 8H), 2.14-2.22 (m, 4H), 3.32-3.36 (m, 2H), 3.42-3.58 (m, 
12H), 4.44 (br s, 1H), 5.29-5.33 (m, 4H), 6.46 (br s, 1H). 
The obtained Boc-protected compound (2.5 g, 2.90 mmol) was dissolved in minimum quantity of 
CH2Cl2 (5 mL) and stirred with 4 N HCl in dioxane (10 mL) for 3 hours. Evaporation of solvent 
afforded the compound 7 as HCl in quantitative yield.  
1
H NMR (500 MHz, CDCl3/2 drops 
CD3OD):  0.88-0.90 (dd, 6H, J = 5.2 and 5.6 Hz), 1.28-1.32 (m, 40H), 1.58-1.61 (m, 4H), 
2.00-2.02 (m, 8H), 2.21-2.28 (m, 4H), 3.15-3.3 (br s, 2H), 3.37-3.47 (m, 1H), 3.63-3.72 (m, 9H), 
3.85-3.86 (m, 2H), 4.6-4.7 (m, 1H), 5.32-5.37 (m, 4H), 7.24 (br s, 1H), 7.73 (d, 1H, J = 5.2Hz), 
8.20 (br s, 1H), 8.36 (br s, 3H). 
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Pyranine lipid: To a DMF (10 mL) solution of compound 7 (0.2 g, 0.25 mmol), cascade 
blue (0.161 g, 0.27 mmol) was added and stirred for 10 minutes to make a homogeneous 
solution. HOBt (0.036 g, 0.27 mmol) followed by EDC (0.052 g, 0.27 mmol) were added to the 
reaction mixture and stirred at room temperature for 36 hours. Solvent was evaporated under 
reduced pressure and little water was added to the residue followed by large excess of isopropyl 
alcohol. The resulting precipitate was filtered, dried and was subjected to chromatographic 
purification using 2:1 dichloromethane methanol mixture (Rf = 0.3) to afforded the pure product 
as a yellow waxy solid (92 mg, 28%). 
 1
H NMR (400 MHz, DMSO-d6): 0.80-0.84 (distorted 
triplet, 6H, J = 7.2 and 6.4 Hz), 1.13-1.31 (m, 40H), 1.40-1.44 (m, 4H), 1.93-2.01 (m, 10H), 
2.05-2.09 (t, 2H, J = 7.6 Hz), 3.14-3.51 (m, 14H), 4.26-4.29 (m, 1H), 4.85 (s, 2H), 5.26-5.31 (m, 
4H), 7.68-7.73 (m,2H), 7.84-7.86 (m, 1H), 8.11 (s, 1H), 8.25-8.28 (m,1H), 8.51 (d, 1H, J = 9.6 
Hz), 8.96 (d, 1H, J = 10 Hz), 9.02-9.04 (m, 2H), 9.15 (d, 1H, J = 9.6 Hz).
 13
C NMR (100 MHz, 
DMSO-d6): 14.95, 22.74, 25.41, 25.76, 25.89, 27.23, 27.30, 29.25, 29.33, 29.49, 29.63, 29.75, 
29.83, 31.94, 36.02, 39.03, 69.50, 69.58, 70.23, 85.59, 109.78, 120.43, 121.37, 121.67, 124.51, 
125.17, 125.69, 126.09, 126.68, 127.01, 128.29, 128.69, 130.26, 130.53, 134.25, 140.29, 140.41, 
143.79, 151.28, 168.18, 170.71, 172.92, 173.43.  MH
+
 calcd. for C63H89N4Na3O16S: 1324.51; 
found: 1324.57. 
Lissamine Rhodamine B lipid: This lipid is commercially available from Avanti Polar 
Lipids, Alabaster, AL. MW = 1267.68 g/mol; λex = 557 nm; λem = 567-700 nm 
Dansyl lipid: This lipid is commercially available from Avanti Polar Lipids, Alabaster, 
AL. MW = 994.35 g/mol; λex = 336 nm; λem = 400-650 nm 
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Figure A2. Fluorescence emission intensity changes of liposomes containing rhodamine 
fluorophore in presence of glycosaminoglycans.  The emission intensity ratios for the 
rhodamine liposomes (λex = 557 nm) in the absence and presence of added GAGs are shown. The 
GAGs include chondroitin sulfate (black squares), dextran sulfate (red circles), heparin sulfate 
(blue triangles), hyaluronic acid (dark cyan inverted triangles), and dermatan sulfate (magenta 
diamonds). The data points are connected by straight lines. 
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Figure A3. Fluorescence emission intensity changes of liposomes containing dansyl 
fluorophore in presence of glycosaminoglycans.  The emission intensity ratios for the dansyl 
liposomes (ex = 336 nm) in the absence and presence of added GAGs are shown. The GAGs 
include chondroitin sulfate (black squares), dextran sulfate (red circles), heparin sulfate (blue 
triangles), hyaluronic acid (dark cyan inverted triangles), and dermatan sulfate (magenta 
diamonds). The data points are connected by straight lines. 
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Figure A4. Comparison of liposome fluorescence emission intensity changes of pyranine-
containing liposomes in the presence of chondroitin sulfate of two molecular weights.  The 
emission intensity ratios for the pyranine liposomes (ex = 415 nm) in the presence of 20kDa 
MW chondroitin sulfate (black squares), and 35kDa MW chondroitin sulfate (red circles). The 
data points are connected by straight lines. 
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Figure A5. Comparison of liposome fluorescence emission intensity changes of dansyl-
containing liposomes in the presence of chondroitin sulfate of two molecular weights. The 
emission intensity ratios for the dansyl liposomes (ex = 587 nm) in the presence of 20kDa MW 
chondroitin sulfate (black squares), and 35kDa MW chondroitin sulfate (red circles). The data 
points are connected by straight lines. 
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Figure A6. Comparison of liposome fluorescence emission intensity changes of rhodamine-
containing liposomes in the presence of chondroitin sulfate of two molecular weights. The 
emission intensity ratios for the rhodamine liposomes (ex = 587 nm) in the presence of 20kDa 
MW chondroitin sulfate (black squares), and 35kDa MW chondroitin sulfate (red circles). The 
data points are connected by straight lines. 
Statistical data analysis 
The following discussion presents the full set of LDA results for the analysis at 50 nM.  
For simplicity, these are labeled as Tables A1-A5 and Figure A1.  Note that several of these 
tables (A1 and A5), Figure A1 and some of the language are identical to those presented in the 
body of the text. 
Linear discriminant analysis (LDA) is used to identify the predictive power of the 
liposomes.  Emissions intensity data from the three liposomes (the predictor variables) and the 
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five GAGs (the dependent variables) were replicated a total of six times, yielding a sample of 30 
observations with four variables (one for each liposome and one identifying the GAG).  Each 
liposome is included in the model using a stepwise procedure, where inclusion is based on 
minimizing the Mahalanobis D
2
, or generalized squared inter-point distance, between each 
individual observation to the corresponding group centroid.  
Once the appropriate number of liposomes is determined, LDA identifies canonical 
correlations (i.e., synthetic variables which are linear combinations of the predictor variables) 
which maximize the ratio of the between-group variation to the within-group variation across the 
GAGs.   That is, LDA identifies the set of predictive factors that leads to maximum 
discrimination between our GAGs.  Note that, for K = 5 possible GAGs, it is possible to identify 
as many as K-1 = 4 possible canonical correlations, and by extension as many as K-1 = 4 
discriminant functions, each of which relates a single canonical correlation to a linear 
combination of liposome fluorescence intensities.  It is common practice to identify and interpret 
only those correlations that are both orthogonal and explain a significant portion of the variation 
in the GAGs.  The coefficients characterizing the linear combination of the predictor variables 
can also be used (with a bit of algebraic manipulation) to identify the relative contribution of 
each liposome to a discriminant function.  Liposomes with larger coefficient values (in absolute 
value) play a larger role in the formation of a given discriminant function, and by extension in 
predicting the GAGs.  To characterize the contribution of each liposome to the model’s overall 
ability to discriminate across GAGs (rather than the ability of a single canonical function), we 
utilize the correlations between each liposome and each of the discriminant functions to generate 
a structure matrix. The elements of the structure matrix are subsequently combined with the 
eigenvalues of canonical functions to generate an overall “potency index” for each liposome.  
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Higher values for each index signal the overall importance of each liposome to the model as a 
whole.     
Overall model fit is assessed by examining canonical function plots to identify whether 
each of the group centroids (one for each of the five GAGs) is sufficiently distinct.  Overlap 
between the data points of two or more groups indicates that the model does not adequately 
discriminate across these GAGs.  Internal validity is assessed by comparing the percentage of 
GAG observations that are correctly predicted by the model.  All model predictions are 
computed using both traditional and (leave one out) cross-validation techniques.  Internally valid 
results should correctly predict a high percentage of observations, and display consistency in 
predicted values across both techniques.  All statistical analyses were conducted using the PASW 
(formerly SPSS) Statistical Package, Version 18.  
Table A1 contains means, F-statistics and Wilks’ Lambda values for each liposome, 
disaggregated by GAGs.  We note in passing that smaller values for the Wilks’ Lambda indicate 
a greater potential for the liposome to discriminate across GAGs.  All F-statistics have associated 
p-values less than 0.05, indicating significant differences exist across group means for each 
GAG.  For the chondroitin sulfate, dextran sulfate, heparin sulfate and hyaluronic acid GAGs, 
the dansyl liposome has the highest mean fluorescence values.  The pyranine liposomes have the 
second highest mean values, followed by rhodamine.  The remaining GAG (dermatan sulfate) 
has the highest mean emission ratios when combined with pyranine, followed by dansyl and 
rhodamine.  Wilks’ Lambda values are lowest for pyranine, followed by rhodamine and dansyl.  
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Table A1. 50 nM LDA tests of equality of group means 
GAG Pyranine
[a,b]
  Rhodamine
[a,b]
    Dansyl
[a,b]
 
Chondroitin Sufate 1.562 1.297 1.563 
Dermatan Sulfate 1.942 1.447 1.412 
Dextran Sulfate 1.334 1.247 1.541 
Heparin Sulfate 1.729 1.517 1.862 
Hyaluronic Acid 1.487 1.124 2.243 
    
Wilks’ Lambda 0.068 0.214 0.560 
F-Statistic [4, 25] 85.829 22.898 4.904 
P-Value <0.001 <0.001 0.005 
[a] first panel provides group-specific means [b] second panel provides statistics and p-values. 
Table A2 contains a summary of the stepwise variable selection process.  All three 
liposomes are found worthy of inclusion, and no variables are removed from the analysis.  Table 
A3 identifies the number of significant canonical correlations, and by extension the number of 
significant canonical functions.  Chi-square tests indicate that three canonical functions are 
sufficient to explain our 5 GAGs.  Of these, the first canonical function is most important, as it 
explains 96.3% of the variation across GAGs.  The remaining functions explain 3.0% and 0.7%, 
respectively.  As such, we focus primarily on the first discriminant function.   
Table A2. 50nM LDA variables in the analysis
[a]
   
Step 
Entered 
Predictor D
2 
Between 
Groups  
F-Statistic P-Value 
1 Pyranine 1.475 1 and 5 4.426 0.046 
2 Dansyl 6.150 3 and 5 8.857 0.001 
3 Rhodamine 12.499 3 and 5 11.499 <0.001 
[a] Variables are entered in a manner that maximizes the Mahalanobis D
2
 between the two 
closest groups. [b] Each of five GAGs groups are: chondroitin sulfate (group 1), dermatan 
sulfate (group 2), dextran sulfate (group 3), heparin sulfate (group 4) and hyaluronic acid 
(group 5). 
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Table A3. 50 nM LDA canonical function summary
[a]
    
Fct. Eigen-Value Pct. of 
Variance 
Explained
 
Canonical 
Correl. 
Wilks’ 
Lambda
[a]
   
Chi-
Square 
Statistic 
P-Value 
1 61.693 96.3 0.992 0.004
[b]
 139.166 <0.001 
2 1.893 3.0 0.809 0.240
[c]
 35.710 <0.001 
3 0.442 0.7 0.554 0.693
[d]
 9.151   0.010 
[a] Lower values for Wilks’ Lambda indicate greater discrimination.  Wilks’ Lambda and chi-
square tests apply sequentially. [b] tests functions 1 – 3 cumulatively.  [c]  tests functions 2 – 3  
cumulatively [d] tests function 3. 
Figure A7 contains a canonical function plot of the first two canonical functions 
(explaining 99.3% of the variation in the GAGs).  Note that each of the GAGs is clearly 
distinguished as a group in the plot.  Moreover, traditional and cross-validated discriminant 
functions corrected predict 100% and 93.3% of the GAGs, respectively, indicating a high 
likelihood of interval validity.    
Table A4 contains the standardized discriminant function coefficients, which measure the 
relative contributions of each liposome to a specific discriminant function.  For function one, the 
dansyl liposome exhibits the largest coefficient in absolute value (signs merely denote the 
magnitude of the relationship) followed closely by the pyranine liposome.  While still 
meaningful (coefficients with values above 0.3 are generally considered “significant” or 
meaningful), the rhodamine liposome is over twice as small as the other two coefficients.  
Concomitantly, rhodamine carries the largest weight in the second canonical function, and is 
twice as large in absolute magnitude compared to the other coefficients.  Lastly, the Dansyl 
liposome has the largest canonical weight in the third canonical function.   
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Figure A7. 50nM LDA canonical correlation plot between two largest canonical 
correlations and each of the five GAGs.  Chondroitin sulfate (group 1), dermatan sulfate 
(group 2), dextran sulphate (group 3), heparin sulphate (group 4) and hyaluronic sulphate (group 
5).  
 
Table A4. 50 nM LDA standardized canonical 
discriminant function coefficients 
Predictor Canonical 
Function 1 
Canonical 
Function 2
 
Canonical 
Function 3 
Pyranine 1.615 -0.478 -0.059 
Rhodamine 0.795 0.924 0.352 
Dansyl -1.708 -0.426 0.811 
 
To assess the overall contribution of each liposome to the discriminatory power of the 
LDA, we present Table A5, which contains the structure matrix and the cumulative potency 
indices. The potency indices suggest that pyranine provides the largest overall contribution to the 
model’s ability to distinguish emission intensities across GAGs. 
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Table A5. 50 nM LDA structure matrix and potency 
index 
 
Predictor Canonical 
Function 1 
Canonical 
Function 2
 
Canonical 
Function 3 
Potency 
Index 
Pyranine 0.456 -0.631 0.628 0.215 
Rhodamine 0.209 0.613 0.762 0.057 
Dansyl -0.057 -0.312 0.948 0.012 
 
On total, the LDA has a clear and intuitive interpretation.  The results in Table A2 
suggest that the first canonical function is, by far, the most important discriminant function.  
Tables A4 and A5 jointly suggest that pyranine is the largest contributor to this discriminant 
function, and to the model overall.  This implies that the pyranine liposome is the “best” 
determinant of GAGs.  Dansyl is identified as the least “potent” discriminator, even though its 
emission intensities are relatively high (Table A1).  The Wilks’ Lambda and structure matrix 
(Table A5) suggest (but do not prove) that this is at least partly attributable to excess variation in 
dansyl emission intensities, which offsets the high mean values.   
The following tables present the full set of LDA results for the analysis at 100 nM.  For 
simplicity, these are labeled as Tables A6 – A10 and Figure A8. Since the discussion of each of 
the following tables is analogous to what was described previously, we simply present the tables 
for the reader’s consumption. 
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Table A7. 100 nM LDA variables in the analysis
[a]
 
  
Step Entered Predictor D
2 
Between Groups  F-Statistic P-Value 
1 Pyranine 0.615 1 and 4 1.845 0.187 
2 Dansyl 4.928 1 and 5    7.097 0.004 
3 Rhodamine 9.514    1 and 4    8.753 <0.001 
[a] Variables are entered in a manner that maximizes the Mahalanobis D
2
 between the two 
closest groups. [b] Each of five GAGs groups are: chondroitin sulfate (group 1), dermatan 
sulfate (group 2), dextran sulfate (group 3), heparin sulfate (group 4) and hyaluronic acid 
(group 5) 
 
Table A8. 100 nM LDA canonical function summary
[a]
    
Fct. Eigen-Value Pct. of 
Variance 
Explained
 
Canonical 
Correl. 
Wilks’ 
Lambda
[a]
   
Chi-
Square 
Statistic 
P-Value 
1 23.726 85.3 0.980 0.006
[b]
 126.396 <0.001 
2   3.749 13.5 0.889 0.158
[c]
 46.199 <0.001 
3 0.336 1.2 0.502 0.748
[d]
 7.250   0.027 
[a] Lower values for Wilks’ Lambda indicate greater discrimination.  Wilks’ Lambda and chi-
square tests apply sequentially. [b] tests functions 1 – 3 cumulatively.  [c]  tests functions 2 – 3  
cumulatively [d] tests function 3. 
 
 
Table A6. 100 nM LDA tests of equality of group means 
GAG Pyranine
[a,b]
  
Rhodamine
[a,b]
    Dansyl
[a,b]
 
Chondroitin Sulfate 1.687 1.315 1.816 
Dermatan Sulfate 2.035 1.495 1.712 
Dextran Sulfate 1.388 1.253 1.728 
Heparin Sulfate 1.766 1.530 2.093 
Hyaluronic Acid 1.551 1.130 2.506 
    
Wilks’ Lambda 0.153 0.209 0.623 
F-Statistic [4,25] 34.489 0.626 3.775 
P-Value <0.001 <0.001 0.016 
[a] first panel provides group-specific means [b] second panel 
provides statistics and p-values. 
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Table A9. 100 nM LDA standardized canonical 
discriminant function coefficients 
Predictor Canonical 
Function 1 
Canonical 
Function 2
 
Canonical 
Function 3 
Pyranine 1.546 -1.117 -0.058 
Rhodamine 0.438 1.412 0.281 
Dansyl -1.686 -0.245 0.830 
 
Table A10. 100 nM LDA structure matrix and potency 
index 
 
Predictor Canonical 
Function 1 
Canonical 
Function 2
 
Canonical 
Function 3 
Potency 
Index 
Pyranine 0.456 -0.308 0.835 0.199 
Rhodamine 0.346 0.435 0.831 0.136 
Dansyl -0.085 -0.169 0.982 0.022 
 
 
Figure A8. 100 nM LDA canonical correlation plot between two largest canonical 
correlations and each of the five GAGs.  Chondroitin sulfate (group 1), dermatan sulfate 
(group 2), dextran sulphate (group 3), heparin sulphate (group 4) and hyaluronic sulfate (group 
5).   
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APPENDIX B. SUPPLIMENTARY INFORMATION FROM PAPER 2 
Example of calculation of total lipid concentration 
MW of DSPC = 790.145 g/mol, MW of Rhodamine lipid = 1,249.641 g/mol 
Concentration of Total Lipid: 
4.0 x 10
-3
 g DSPC x 1 mol/760.076 g = 5.26 x 10
-6 
mol 
6.5 x 10
-5
 g rhodamine lipid x 1 mol/ 1,249.641 g = 5.2 x 10
-8
 mol 
5.26 x 10
-6 
mol + 5.2 x 10
-8 
= 5.312 x 10
-6
 mol  
5.312 x 10
-6 
mol/3.8 mL = 1.4 x 10
-6 
mol/mL 
1.4 x 10
-6 
mol/mL x 1000mL/L = 1.4 x 10
-3 
mol/L      
=  1.4 mM 
Statistical analysis 
All statistical analysis was carried out using Minitab (version 16.1.1, State College, PA).  
Raw data from the Zetasizer Nano (Malvern, Westborough, MA), including measurements of 
average diameter and zeta potential, were entered into the Minitab spreadsheets, and analysis 
was carried out using these numbers in their original form.   
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Minitab spreadsheets 
One-way ANOVA: 200 nm liposomes OSCS size versus contamination:  
 
Source         DF        SS       MS       F      P 
contamination   8  11431736  1428967  103.26  0.000 
Error          36    498172    13838 
Total          44  11929908 
 
S = 117.6   R-Sq = 95.82%   R-Sq(adj) = 94.90% 
 
 
                         Individual 95% CIs For Mean Based on 
                         Pooled StDev 
Level  N    Mean  StDev  --+---------+---------+---------+------- 
 0.0   5   540.8   50.5   (-*-) 
 0.5   5   502.2   37.0  (-*-) 
 1.0   5   661.2  103.8     (-*-) 
 2.5   5   689.1  129.4      (-*-) 
 5.0   5  1013.6   65.5            (-*-) 
10.0   5  1458.0  116.3                     (-*-) 
15.0   5  1374.4  139.8                   (-*--) 
20.0   5  1696.8  196.0                          (-*-) 
30.0   5  1929.4  131.7                              (--*-) 
                         --+---------+---------+---------+------- 
                         500      1000      1500      2000 
Pooled StDev = 117.6 
Grouping Information Using Dunnett Method 
 
Level           N    Mean  Grouping 
 0.0 (control)  5   540.8  A 
30.0            5  1929.4 
20.0            5  1696.8 
10.0            5  1458.0 
15.0            5  1374.4 
 5.0            5  1013.6 
 2.5            5   689.1  A 
 1.0            5   661.2  A 
 0.5            5   502.2  A 
 
Means not labeled with letter A are significantly different from control 
level mean. 
 
 
Dunnett's comparisons with a control 
 
Family error rate = 0.05 
Individual error rate = 0.0084 
 
Critical value = 2.79 
 
Control = level (0) of contamination 
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Intervals for treatment mean minus control mean 
 
Level   Lower  Center   Upper  -----+---------+---------+---------+---- 
 0.5   -246.0   -38.6   168.9  (---*---) 
 1.0    -87.0   120.5   327.9     (---*----) 
 2.5    -59.1   148.3   355.8      (---*---) 
 5.0    265.4   472.9   680.3            (---*----) 
10.0    709.8   917.2  1124.7                     (---*---) 
15.0    626.2   833.6  1041.1                    (---*---) 
20.0    948.6  1156.0  1363.5                          (---*---) 
30.0   1181.2  1388.6  1596.1                               (---*---) 
                               -----+---------+---------+---------+---- 
                                    0       500      1000      1500 
 
 
   
One-way ANOVA: 200 nm liposome OSD size versus contamination:  
 
Source         DF       SS      MS      F      P 
contamination   8  4679965  584996  59.78  0.000 
Error          36   352295    9786 
Total          44  5032260 
 
S = 98.92   R-Sq = 93.00%   R-Sq(adj) = 91.44% 
 
 
                         Individual 95% CIs For Mean Based on 
                         Pooled StDev 
Level  N    Mean  StDev  -------+---------+---------+---------+-- 
 0.0   5   540.8   50.5    (--*--) 
 0.5   5   483.2   63.8  (--*--) 
 1.0   5   674.9  108.3         (-*--) 
 2.5   5   656.9   73.6        (--*--) 
 5.0   5   609.1   64.5      (--*--) 
10.0   5   947.4   83.4                  (--*--) 
15.0   5  1132.4  134.0                        (--*--) 
20.0   5  1312.0   90.6                              (--*--) 
30.0   5  1377.2  164.4                                (--*--) 
                         -------+---------+---------+---------+-- 
                              600       900      1200      1500 
 
Pooled StDev = 98.9 
 
Grouping Information Using Dunnett Method 
 
Level           N    Mean  Grouping 
 0.0 (control)  5   540.8  A 
30.0            5  1377.2 
20.0            5  1312.0 
15.0            5  1132.4 
10.0            5   947.4 
 1.0            5   674.9  A 
 2.5            5   656.9  A 
 5.0            5   609.1  A 
 0.5            5   483.2  A 
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Means not labeled with letter A are significantly different from control 
level mean. 
Dunnett's comparisons with a control 
 
Family error rate = 0.05 
Individual error rate = 0.0084 
 
Critical value = 2.79 
 
Control = level (0) of contamination 
 
Intervals for treatment mean minus control mean 
 
Level   Lower  Center   Upper  -------+---------+---------+---------+-- 
 0.5   -232.1   -57.6   116.9  (----*----) 
 1.0    -40.3   134.1   308.6        (----*----) 
 2.5    -58.3   116.2   290.6       (----*----) 
 5.0   -106.1    68.4   242.8      (----*----) 
10.0    232.2   406.6   581.1                (----*----) 
15.0    417.2   591.6   766.1                     (----*----) 
20.0    596.8   771.2   945.7                          (----*----) 
30.0    662.0   836.4  1010.9                            (----*----) 
                               -------+---------+---------+---------+-- 
                                      0       350       700      1050 
 
 
One-way ANOVA: 200 nm liposome OSCS zeta versus contamination:  
 
Source         DF      SS     MS      F      P 
contamination   8  34.117  4.265  20.28  0.000 
Error          36   7.571  0.210 
Total          44  41.688 
 
S = 0.4586   R-Sq = 81.84%   R-Sq(adj) = 77.80% 
 
 
                          Individual 95% CIs For Mean Based on 
                          Pooled StDev 
Level  N    Mean   StDev  --+---------+---------+---------+------- 
 0.0   5  4.6280  0.5840                (---*---) 
 0.5   5  3.9260  0.3182         (---*---) 
 1.0   5  5.5340  0.8384                         (---*---) 
 2.5   5  4.0040  0.1435          (---*---) 
 5.0   5  3.2480  0.4206  (---*----) 
10.0   5  3.9140  0.3577         (---*---) 
15.0   5  5.2860  0.2964                       (---*---) 
20.0   5  5.8180  0.4274                            (---*---) 
30.0   5  5.5580  0.3892                         (----*---) 
                          --+---------+---------+---------+------- 
                          3.0       4.0       5.0       6.0 
 
Pooled StDev = 0.4586 
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Grouping Information Using Dunnett Method 
 
Level           N    Mean  Grouping 
 0.0 (control)  5  4.6280  A 
20.0            5  5.8180 
30.0            5  5.5580 
 1.0            5  5.5340 
15.0            5  5.2860  A 
 2.5            5  4.0040  A 
 0.5            5  3.9260  A 
10.0            5  3.9140  A 
 5.0            5  3.2480 
 
Means not labeled with letter A are significantly different from control 
level mean. 
 
 
Dunnett's comparisons with a control 
 
Family error rate = 0.05 
Individual error rate = 0.0084 
 
Critical value = 2.79 
 
Control = level (0) of contamination 
 
Intervals for treatment mean minus control mean 
 
Level    Lower   Center    Upper  --------+---------+---------+---------+- 
 0.5   -1.5107  -0.7020   0.1067       (------*------) 
 1.0    0.0973   0.9060   1.7147                     (------*-----) 
 2.5   -1.4327  -0.6240   0.1847        (------*------) 
 5.0   -2.1887  -1.3800  -0.5713  (-----*------) 
10.0   -1.5227  -0.7140   0.0947       (------*------) 
15.0   -0.1507   0.6580   1.4667                   (-----*------) 
20.0    0.3813   1.1900   1.9987                       (------*------) 
30.0    0.1213   0.9300   1.7387                     (------*-----) 
                                  --------+---------+---------+---------+- 
                                       -1.2       0.0       1.2       2.4 
 
One-way ANOVA: 200 nm liposomes OSD zeta versus contamination:  
 
Source         DF      SS    MS     F      P 
contamination   8   41.03  5.13  3.12  0.009 
Error          36   59.23  1.65 
Total          44  100.26 
 
S = 1.283   R-Sq = 40.92%   R-Sq(adj) = 27.79% 
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                        Individual 95% CIs For Mean Based on 
                        Pooled StDev 
Level  N   Mean  StDev  -------+---------+---------+---------+-- 
 0.0   5  4.628  0.584                      (-------*-------) 
 0.5   5  4.604  0.528                      (-------*------) 
 1.0   5  1.656  3.078  (-------*-------) 
 2.5   5  4.716  0.742                       (------*-------) 
 5.0   5  4.830  0.857                       (-------*-------) 
10.0   5  4.872  0.984                        (------*-------) 
15.0   5  4.590  0.738                      (-------*------) 
20.0   5  4.672  1.133                      (-------*-------) 
30.0   5  4.446  0.796                     (-------*------) 
                        -------+---------+---------+---------+-- 
                             1.5       3.0       4.5       6.0 
 
Pooled StDev = 1.283 
 
Grouping Information Using Dunnett Method 
 
Level           N   Mean  Grouping 
 0.0 (control)  5  4.628  A 
10.0            5  4.872  A 
 5.0            5  4.830  A 
 2.5            5  4.716  A 
20.0            5  4.672  A 
 0.5            5  4.604  A 
15.0            5  4.590  A 
30.0            5  4.446  A 
 1.0            5  1.656 
 
Means not labeled with letter A are significantly different from control 
level mean. 
 
Dunnett's comparisons with a control 
 
Family error rate = 0.05 
Individual error rate = 0.0084 
 
Critical value = 2.79 
 
Control = level (0) of contamination 
 
Intervals for treatment mean minus control mean 
 
Level   Lower  Center   Upper  ------+---------+---------+---------+--- 
 0.5   -2.286  -0.024   2.238                 (----------*----------) 
 1.0   -5.234  -2.972  -0.710  (----------*----------) 
 2.5   -2.174   0.088   2.350                 (----------*-----------) 
 5.0   -2.060   0.202   2.464                  (----------*----------) 
10.0   -2.018   0.244   2.506                  (----------*-----------) 
15.0   -2.300  -0.038   2.224                (-----------*----------) 
20.0   -2.218   0.044   2.306                 (----------*-----------) 
30.0   -2.444  -0.182   2.080                (----------*----------) 
                               ------+---------+---------+---------+--- 
                                  -4.0      -2.0       0.0       2.0 
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One-way ANOVA: OSCS size versus contamination:  
 
Source         DF       SS      MS     F      P 
contamination   8  4087429  510929  4.57  0.001 
Error          36  4026851  111857 
Total          44  8114280 
 
S = 334.5   R-Sq = 50.37%   R-Sq(adj) = 39.35% 
 
 
                         Individual 95% CIs For Mean Based on Pooled StDev 
Level  N    Mean  StDev    -+---------+---------+---------+-------- 
 0.0   5  3223.6  645.7                            (-------*------) 
 0.5   5  2754.2  479.3                (-------*------) 
 1.0   5  2903.2  207.2                    (-------*------) 
 2.5   5  2416.8  273.9        (------*-------) 
 5.0   5  2361.0  297.0      (-------*-------) 
10.0   5  2370.4  136.9       (------*-------) 
15.0   5  2452.6  260.4         (------*-------) 
20.0   5  2268.2  204.7    (-------*------) 
30.0   5  2387.0  159.5       (-------*------) 
                           -+---------+---------+---------+-------- 
                         2000      2400      2800      3200 
 
Pooled StDev = 334.5 
 
 
Grouping Information Using Dunnett Method 
 
Level           N    Mean  Grouping 
 0.0 (control)  5  3223.6  A 
 1.0            5  2903.2  A 
 0.5            5  2754.2  A 
15.0            5  2452.6 
 2.5            5  2416.8 
30.0            5  2387.0 
10.0            5  2370.4 
 5.0            5  2361.0 
20.0            5  2268.2 
 
Means not labeled with letter A are significantly different from control 
level mean. 
Dunnett's comparisons with a control 
 
Family error rate = 0.05 
Individual error rate = 0.0084 
 
Critical value = 2.79 
 
Control = level (0) of contamination 
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Intervals for treatment mean minus control mean 
 
Level    Lower  Center   Upper     -+---------+---------+---------+-------- 
 0.5   -1059.2  -469.4   120.4               (-----------*----------) 
 1.0    -910.2  -320.4   269.4                  (-----------*----------) 
 2.5   -1396.6  -806.8  -217.0        (-----------*-----------) 
 5.0   -1452.4  -862.6  -272.8       (-----------*-----------) 
10.0   -1443.0  -853.2  -263.4       (-----------*-----------) 
15.0   -1360.8  -771.0  -181.2         (-----------*----------) 
20.0   -1545.2  -955.4  -365.6     (-----------*-----------) 
30.0   -1426.4  -836.6  -246.8       (-----------*-----------) 
                                   -+---------+---------+---------+-------- 
                                -1500     -1000      -500         0 
 
  
One-way ANOVA: OSD size versus contamination:  
 
Source         DF       SS      MS     F      P 
contamination   8  3786045  473256  5.67  0.000 
Error          36  3005050   83474 
Total          44  6791094 
 
S = 288.9   R-Sq = 55.75%   R-Sq(adj) = 45.92% 
 
                         Individual 95% CIs For Mean Based on 
                         Pooled StDev 
Level  N    Mean  StDev  ---+---------+---------+---------+------ 
 0.0   5  3223.6  645.7                             (------*-----) 
 0.5   5  2337.0  181.5       (-----*------) 
 1.0   5  2446.6  284.2          (-----*------) 
 2.5   5  2667.6  210.3               (------*-----) 
 5.0   5  2439.2  276.9         (------*------) 
10.0   5  2155.4  138.6  (------*-----) 
15.0   5  2355.2  150.5       (------*-----) 
20.0   5  2564.6  136.4             (-----*------) 
30.0   5  2331.0  198.1       (-----*------) 
                         ---+---------+---------+---------+------ 
                         2000      2400      2800      3200 
Pooled StDev = 288.9 
 
Grouping Information Using Dunnett Method 
 
Level           N    Mean  Grouping 
 0.0 (control)  5  3223.6  A 
 2.5            5  2667.6 
20.0            5  2564.6 
 1.0            5  2446.6 
 5.0            5  2439.2 
15.0            5  2355.2 
 0.5            5  2337.0 
30.0            5  2331.0 
10.0            5  2155.4 
 
Means not labeled with letter A are significantly different from control 
level mean. 
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Dunnett's comparisons with a control 
 
Family error rate = 0.05 
Individual error rate = 0.0084 
 
Critical value = 2.79 
 
Control = level (0) of contamination 
 
Intervals for treatment mean minus control mean 
 
Level    Lower   Center   Upper  ---------+---------+---------+---------+ 
 0.5   -1396.1   -886.6  -377.1      (------------*------------) 
 1.0   -1286.5   -777.0  -267.5         (------------*-----------) 
 2.5   -1065.5   -556.0   -46.5              (------------*------------) 
 5.0   -1293.9   -784.4  -274.9         (-----------*------------) 
10.0   -1577.7  -1068.2  -558.7  (-----------*------------) 
15.0   -1377.9   -868.4  -358.9       (-----------*------------) 
20.0   -1168.5   -659.0  -149.5            (------------*-----------) 
30.0   -1402.1   -892.6  -383.1      (------------*-----------) 
                                 ---------+---------+---------+---------+ 
                                      -1200      -800      -400         0 
 
 
One-way ANOVA: OSCS zeta versus contamination:  
 
Source         DF      SS     MS      F      P 
contamination   8  426.64  53.33  31.69  0.000 
Error          36   60.59   1.68 
Total          44  487.24 
 
S = 1.297   R-Sq = 87.56%   R-Sq(adj) = 84.80% 
 
                         Individual 95% CIs For Mean Based on 
                         Pooled StDev 
Level  N    Mean  StDev  ---+---------+---------+---------+------ 
 0.0   5   3.480  1.185                                 (---*---) 
 0.5   5   2.140  1.613                            (---*---) 
 1.0   5   1.155  1.198                         (---*---) 
 2.5   5  -0.030  1.357                     (---*---) 
 5.0   5  -0.990  1.348                  (---*---) 
10.0   5  -2.508  1.327             (---*---) 
15.0   5  -3.614  1.205         (---*---) 
20.0   5  -5.208  1.149    (---*---) 
30.0   5  -5.864  1.231  (--*---) 
                         ---+---------+---------+---------+------ 
                         -6.0      -3.0       0.0       3.0 
 
Pooled StDev = 1.297 
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Grouping Information Using Dunnett Method 
 
Level           N    Mean  Grouping 
 0.0 (control)  5   3.480  A 
 0.5            5   2.140  A 
 1.0            5   1.155 
 2.5            5  -0.030 
 5.0            5  -0.990 
10.0            5  -2.508 
15.0            5  -3.614 
20.0            5  -5.208 
30.0            5  -5.864 
 
Means not labeled with letter A are significantly different from control 
level mean. 
 
 
Dunnett's comparisons with a control 
 
Family error rate = 0.05 
Individual error rate = 0.0084 
 
Critical value = 2.79 
 
Control = level (0) of contamination 
 
Intervals for treatment mean minus control mean 
 
Level    Lower  Center   Upper   ---+---------+---------+---------+------ 
 0.5    -3.627  -1.340   0.948                          (-----*------) 
 1.0    -4.613  -2.325  -0.037                       (-----*------) 
 2.5    -5.798  -3.510  -1.222                   (------*------) 
 5.0    -6.758  -4.470  -2.182                 (-----*------) 
10.0    -8.276  -5.988  -3.700            (------*-----) 
15.0    -9.382  -7.094  -4.806         (------*-----) 
20.0   -10.976  -8.688  -6.400     (-----*------) 
30.0   -11.632  -9.344  -7.056   (-----*------) 
                                 ---+---------+---------+---------+------ 
                                -10.5      -7.0      -3.5       0.0 
 
 
One-way ANOVA: OSD zeta versus contamination:  
 
Source         DF      SS     MS      F      P 
contamination   8  432.89  54.11  21.55  0.000 
Error          36   90.40   2.51 
Total          44  523.28 
 
S = 1.585   R-Sq = 82.73%   R-Sq(adj) = 78.89% 
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 Individual 95% CIs For Mean Based on 
                         Pooled StDev 
Level  N    Mean  StDev  -----+---------+---------+---------+---- 
 0.0   5   3.480  1.185                                 (---*---) 
 0.5   5   2.263  1.245                             (---*----) 
 1.0   5   2.016  0.859                             (---*---) 
 2.5   5   1.578  1.656                           (----*---) 
 5.0   5   1.125  1.275                          (---*---) 
10.0   5  -0.936  1.950                    (---*---) 
15.0   5  -1.126  1.965                    (---*---) 
20.0   5  -2.670  1.538               (---*---) 
30.0   5  -7.246  2.124  (---*---) 
                         -----+---------+---------+---------+---- 
                           -7.0      -3.5       0.0       3.5 
 
Pooled StDev = 1.585 
 
Grouping Information Using Dunnett Method 
 
Level           N    Mean  Grouping 
 0.0 (control)  5   3.480  A 
 0.5            5   2.263  A 
 1.0            5   2.016  A 
 2.5            5   1.578  A 
 5.0            5   1.125  A 
10.0            5  -0.936 
15.0            5  -1.126 
20.0            5  -2.670 
30.0            5  -7.246 
 
Means not labeled with letter A are significantly different from control 
level mean. 
Dunnett's comparisons with a control 
 
Family error rate = 0.05 
Individual error rate = 0.0084 
 
Critical value = 2.79 
 
Control = level (0) of contamination 
 
Intervals for treatment mean minus control mean 
 
Level    Lower   Center   Upper  ----+---------+---------+---------+----- 
 0.5    -4.011   -1.217   1.578                          (------*------) 
 1.0    -4.258   -1.464   1.330                         (------*------) 
 2.5    -4.696   -1.902   0.893                        (------*------) 
 5.0    -5.149   -2.355   0.440                       (------*------) 
10.0    -7.210   -4.416  -1.622                  (------*------) 
15.0    -7.401   -4.606  -1.812                 (------*------) 
20.0    -8.944   -6.150  -3.356              (------*------) 
30.0   -13.520  -10.726  -7.932  (------*------) 
                                 ----+---------+---------+---------+----- 
                                 -12.0      -8.0      -4.0       0.0 
 
